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 Cryptosporidium causes cryptosporidiosis, a self-limiting diarrheal disease in 
healthy people, but causes serious health issues for immunocompromised individuals.  
Cryptosporidiosis has been observed in humans since the early 1970s and continues to 
cause public health concerns. Cryptosporidium has a complicated life cycle making 
laboratory study challenging.  This project explores several ways of studying 
Cryptosporidium parvum, with a goal of applying existing techniques to further 
understand this life cycle.  Utilization of a neonatal mouse model demonstrated laser 
microdissection as a tool for studying host immune response to infeciton.  A cell culture 
technique developed on FrameSlides™ enables laser microdissection of individual infected 
cells for further analysis. Finally, the hypothesis that the availability of cells to infect drives 
the switch from asexual to sexual parasite reproduction was tested by time-series 
infection.  The results suggest this isn’t accurate.  These experiments open the door to 
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When starting to work on Cryptosporidium, two things were evident. First, 
cryptosporidiosis is a disease of increasing importance. In immunocompetent individuals, 
it is normally a self-limiting disease, but can be one of life-threatening impact as more and 
more individuals live longer with compromised immunity. Next, there is a great deal left to 
be discovered about Cryptosporidium sp. due to a complex life cycle that hampers many of 
the fundamental characterizations that are available for most pathogens.  
This thesis is structured in two parts. It will thoroughly review the available 
Cryptosporidium literature, describing the taxonomy and biology of the parasite itself, as 
well as the disease that it causes and treatment options.  A description of past and future 
research will be presented, highlighting the challenges faced by researchers investigating 
this unique organism. While many of the experiments that are illustrated in this 
manuscript will need further modification, they represent my contribution to providing 
research tools to further this field of research. 
Introduction 
Discovered in 1907 in the gastric glands and ilea of mice (Tyzzer, 1907, 1910), 
Cryptosporidium was not recognized as a human pathogen until 1973, when an 
immunocompetent child presented with gastroenteritis and Cryptosporidium oocysts in 
his stools (Nime, 1976).  Cryptosporidiosis is a disease caused by the Cryptosporidium 
parasite and is marked by severe, watery diarrhea that, in otherwise healthy humans or 
other animals, can last up to two weeks (O’Donoghue, 1995).  Infected individuals may also 
have severe cramping, nausea, vomiting, dehydration, and fever (Thompson et al., 2005).  
Cryptosporidiosis can be life threatening in immunocompromised patients, and it has 
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become a major public health concern particularly in HIV-infected individuals living with 
compromised immune systems (Casemore, 1985, Guerrant, 1997).  Two species of 
Cryptosporidium are known to cause the majority of cases of human cryptosporidiosis; 
Cryptosporidium hominis, which primarily infects only humans, and Cryptosporidium 
parvum, which can infect humans as well as several domestic animal species, including 
cattle (Ernest, et al., 1986., Zu, et al., 1992).     
Nitazoxanide is currently used to treat cryptosporidiosis in immunocompetent 
patients, ameliorating symptoms and decreasing parasite-clearance time, but    
chemotherapeutic options for treating chronic cryptosporidiosis are limited in patients 
with poor immune systems (Blagburn, Soave 1997, Rossignol, 2010).  For example, 
nitazoxanide has proved to be ineffective in AIDS patients with very low T cell counts.  To 
improve efficacy, HIV-positive patients must first undergo highly active anti-retrovirus 
(HAART) treatment to restore immune function (Amadi, B., et al., 2002, Gomez-Morales, 
2004).  Current research exploring new chemical derivatives of Nitazoxanide shows 
increased anti-cryptosporidial action, even in immunocompromised hosts (Gargala, et al., 
2010, Gargala, 2008, Ballard, et al., 2010).   
Basic research and potential treatment advances are hindered by the complex life 
cycle of the parasite, which limits in vivo modeling, and the lack of an effective method for 
its propagation in vitro.  In vivo models are limited to larger young animals, such as a calf, 
which can provide a sustained C. parvum infection and a short-term mouse model, which 
can be used for limited propagation. Unfortunately, each has major drawbacks. Calves are 
large and expensive research animals, which are not easily housed in laboratory 
environments.  C. hominis infects only humans, which is one reason that C. parvum is used 
frequently in lab study.  Neonatal and genetically immunocompromised mice that can be 
infected with Cryptosporidium sp. provide only a short temporal reflection of the 
parasite’s interaction with the host. This model cannot replicate the disease process in the 
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context of a host response since the model necessitates the absence of a competent host 
response.  The lack of an effective lab model is one of the largest challenges currently 
facing Cryptosporidium researchers. 
Cryptosporidium classification and taxonomy 
 When E. E. Tyzzer first observed Cryptosporidium in the intestines and gastric 
ducts of mice, he classified it as a Coccidiomorpha in the phylum Sporozoa due to 
similarities in the life cycle of coccidian parasites.  He named it Cryptosporidium due to 
the appearance of ‘hidden’ sporozoites in the infectious oocyst (Tyzzer, 1910).  Tyzzer 
discussed the similarity of the newly identified organism’s life cycle to gregarines in that 
the majority of these organisms’ life cycles were spent either attached to the epithelial 
surface or free within the gastric glands and intestines.  Although he did not think that the 
parasite penetrated the host cell, he classified it with the coccidians (Tyzzer, 1910).  In 
addition, Cryptosporidium parasites possess a unique feeder organelle (Figure 1) that 
distinguishes it from other coccidians (Hampton and Rosario, 1966).  It was not until 1996 
that Cryptosporidium species were noted to be intracellular, but extracytoplasmic, 
parasites (Goodgame, 1996).  Based on electron microscopic observations, the phylum has 
been changed to Apicomplexa (Levine, 1988).  Cryptosporidium species are classified as 
follows in Table 1 (Fayer, 2008). 
 












 Apicomplexans are characterized by the apical congregation of organelles that 
function in parasite motility and invasion of host cells during infection.  Cryptosporidium 
sporozoites and merozoites, the cell-invading stages, possess an apical secretory complex 
that is typical of the phylum.  In Cryptosporidium, this complex is made up of a single 
rhoptry and multiple micronemes.  In collaboration with receptors on the host’s cells 
(Langer and Riggs, 1999), proteins extruded from the apical secretory complex assist in 
attachment (Chen, et al., 2004) and help to remodel the host cell membrane into an 
intracellular, but extracytoplasmic, parasitophorous vacuole in which the parasite matures 
(O’Hara, et al., 2005).   
 Host-pathogen specificity was thought to be absolute, and as new strains were 
discovered, they were named based on their host and oocyst morphology.  The need for 
more accurate species identification was obvious when it was recognized that a single 
Cryptosporidium species could infect multiple host species (Levine, 1988).  Genetic 
analysis first utilized restriction fragment length polymorphism, identifying isolates based 
on variability in fragment lengths after cleavage with restriction enzymes, which allowed 
differentiation between species that had similar oocyst morphology and host affinity 
 
Figure 1. The unique feeder 
organelle of Cryptosporidium 
sp.  The feeder organelle (arrow) is 
made up of lamella which becomes 
folded at the attachment site.  The 
feeder organelle may function to 
provide sustenance for the 
developing stages of the parasite 
and to communicate between host 
and parasite. (Pohlenz, et al., 1978). 
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(McLauchlin, et al., 2000; Xiao, et al., 2001).  Several polymorphic loci have been 
identified by genome sequencing, making subgenotyping possible (Spano, et al., 1997; 
Xiao, et al., 1999).  Polymorphic genes used to identify Cryptosporidium species include 
those for Cryptosporidium oocyst wall proteins (COWP1 - 9), the18S small subunit (SSU) 
rRNA, thrombospondin-related adhesive protein (TRAP), and heat shock protein-70 
(HSP70).  These have been recognized as having distinct, species-specific differences 
(Templeton and Kaslow, 1997; Robson et al., 1998; Spano, et al., 1997).  As genetic analysis 
has enabled more accurate classification of species, occasionally separately identified 
species have been consolidated to one species with a more diverse host range than 
originally reported (McLauchlin, et al., 2000; Kiao, et al., 2001).  In contrast, some 
genotypes or subspecies have been reclassified as separate species when genetic analysis 
revealed that they were less closely related than assumed (Fayer, et al., 2008) or combined 
species or genotypes when differences between the organisms have not been great enough 
to maintain their status as discrete species.   
 The application of sequence analysis causes the number of recognized species and 
genotypes to adjust almost continually.  In 2000, Fayer and colleagues (2000) published a 
report recognizing 10 species (Fayer, 2000).  In 2004, Fayer recognized 15 species with 
multiple sub-types and sub-species (Fayer, 2004).  The most recent classification of 
Cryptosporidium taxonomy lists 25 species and 40 genotypes (Fayer, 2010).  The Fayer 
paper sets forth guidelines in classification and naming of new species of 
Cryptosporidium.  Table 2 lists the currently recognized species, arranged by host type 
(Fayer, 2010).   
The Cryptosporidium life cycle 
Cryptosporidium has a complex life cycle, which includes an exogenous, infectious 
cycle and an endogenous, intracellular parasitic cycle.  It undergoes both asexual and 
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sexual reproduction within its host.  There is also research indicating that there may be 
extracellular life stages  (Carreno, et al., 1999; Hijjawi, et al., 2002; Rosales, et al., 2005).  
Hijjawi has successfully cultured Cryptosporidium in host cell-free cultures, although this 
has proven difficult to replicate by other researchers (Hijjawi, et al., 2002; Girouard, 
2006; Zhang, et al., 2009). 
Cryptosporidium is a monoxenous parasite, undergoing all life stages, including 
sexual and asexual reproduction, within a single host (O’Donoghue, 1995).  The infectious, 
environmental oocyst stage is ingested by the host and contains four sporozoites 
(Ostrovska K. & Paperna I. 1990; Itakura, C., 1985).  Asexual reproduction produces Type I 
meronts and allows the parasite to rapidly proliferate, and Type II meronts, which are 
believed to give rise to microgametes and macrogametes, which signal the start of sexual 
reproduction.  When a microgamete fertilizes a macrogamete, a zygote is formed, which 
matures into an oocyst containing four sporozoites.  There are two distinct types of 
oocysts:  thin-walled oocysts that promote an autoinfection cycle and thick-walled, 
environmentally robust oocysts that are shed in the feces and that may infect new hosts 
(Current, 1985; Current & Reese, 1986).  There are variations between species as to the site 
of infection within the host (Thompson, 2003; Xiao, 2004).  Cryptosporidium’s life cycle 
is illustrated in Figure 2, and Table 3 lists species by their site of infection.   
Ingestion, excystation, and attachment 
Upon ingestion, the Cryptosporidium oocyst is able to resist the low pH of stomach 
acids and the chemical environment of digestive bile in its travel to the small intestine, 
where it excysts. Research suggests that the reducing conditions in the stomach and small 
intestine affect the oocyst wall, thinning it in preparation for excystation (Chen et al., 
2004).  In the intestine, terminal sialic acid residues on the epithelial cells of the small 
intestine react with receptors on the oocyst, triggering excystation (Choudhry, 2008).  The 
layers of the oocyst peel back from the suture line and create an opening (Valigurová, A., et 
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al., 2008).  Sporozoites escape through this opening and infect nearby epithelial 
cells(Reduker, et al., 1985; Fayer, et al., 1997; Smith, et al., 2005).  An image of sporozoites 
escaping an oocyst is shown in Figure 3.   
 
Table 2.  Cryptosporidium species by host type 
Cryptosporidium species reported from fish 
Species Name  Host (species) Reference 
C. molnari Sparus aurata (Gilthead Seabream) Alvarez-Pellitero and 
Sitja-Bobadilla (2002) 
C. scophthalmi Scophthalmi maximus (turbot) Alvarez-Pellitero et al., 
(2004) 
Cryptosporidium species reported from amphibian and reptiles 
Species Name  Host (species) Reference 
C. serpentis  Corn Snake (Elaphe guttata) Levine (1980) 
C. varanii  Emerald Monitor (Varanus prasinus) Pavlásek et al. (1995) 
C. fragile  Black-spined toad (Duttaphrynus 
melanostictus) 
Jirku et al. (2008) 
Cryptosporidium species reported from birds  
Species Name Host (species) Reference 
C. meleagridis  Turkey (Meleagris gallopavo) Slavin (1955) 
C. baileyi   Chicken (Gallus gallus) Current et al. (1986) 
C. galli   Chicken (Gallus gallus) Pavlásek (1999) 
Cryptosporidium species reported from mammals 
Species Name Host (species) Reference 
C. muris  Mouse (Mus musculus) Tyzzer (1907) 
C. parvum  Mouse (Mus musculus) Tyzzer (1912) 
C. wrairi  Guinea pig (Cavia porcellus) Vetterling et al. (1971) 
C. felis  Cat (Felis catis) Iseki (1979) 
C. andersoni  Cattle (Bos taurus) Lindsay et al. (2000) 
C. canis Dog (Canis familiaris) Fayer et al. (2001) 
 C. hominis  Human (Homo sapiens) 
Morgan-Ryan et al. 
(2002) 
C. suis  Pig (Sus scrofa) Ryan et al. (2004a) 
C. bovis  Cattle (Bos taurus) Fayer et al. (2005) 
C. fayeri Kangaroo (Macropus rufus) Ryan et al. (2008) 
 C. ryanae  Cattle (Bos taurus) Fayer et al. (2008) 
C. 
macropodum  





The gliding motility of sporozoites and merozoites is not fully understood.  It is 
known that during the  stages, when sporozoites or merozoites are employing gliding 
motility, the organelles in the apical complex extrude proteins that play a role in gliding 
motility.  Actin polymerization and a myosin motor within the sporozoite function to move 
the sporozoite along the surface of the host cell.  Receptors on the parasite attach to 
ligands on the host cell and are translocated by an actin/myosin complex to move it along  
(Sibley, 2004, Choudhry, 2008).  The sporozoites orient themselves with their apical end 
towards the surface of the epithelial cells during invasion (Tzipori, 1998). 
 
Figure 2.   Schematic representation of Cryptosporidium life cycle.  Both 
exogenous and endogenous, as well as sexual and asexual, stages are shown.  Infectious 
oocysts are ingested and excyst within the small intestine.  Sporozoites attach to host cells, 
becoming enveloped by host cell membrane.  Trophozoites undergo merogony, developing 
into Type I or Type II meronts.  Type I meronts produce 6-8 merozoites that go on to 
infect more cells, continuing the asexual reproductive stages.  Type II meronts product 4 
merozoites that infect more cells and differentiate into microgamonts and macrogamonts 
that carry out the sexual reproductive stage.  Microgamonts product 16 microgametes, 
while macrogamonts develop into single-nucleated macrogametes.  Microgametes attach 
and enter cells containing macrogametes and fertilization produces zygotes.  The zygotes 
develop into oocysts containing 4 sporozoites.  Thick-walled oocysts are shed in the feces.  
Thin-walled oocysts excyst within the host, and autoinfection continues the life cycle. 
(Adapted from Centers for Disease Control and Prevention, Current and Garcia 1991). 
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* Has been shown to cause human cryptosporidiosis 
 
The Cryptosporidium apical complex is made up of several organelles; a single 
rhoptry, multiple micronemes and dense granules.  These organelles are extruded from the 
apical end of the sporozoite and their secretions enhance gliding motility and attachment, 
and are critical for invasion of host cells (Chen, 2004, Bonnin, et al., 1993, Petersen, et al., 
1992, Tomely and Soldadi, 2001).  There are large numbers of micronemes present in 
Table 3.  List of Cryptosporidium species and site of infection 
Species Site of infection Reference 
C. andersoni Stomach  [Lindsay, D.S., et al., 2000] 
C. baileyi* Trachea, bursa of Fabricius, 
cloacae  
[Current, W.L. et al.,1986] 
C. bovis Unknown [Fayer, R. et al., 2005] 
C. canis* Small intestine  [Fayer, R. et al.,2001] 
C. fayeri Unknown [Ryan, et al., 2008] 
C. felis* Small intestine  [Iseki, M.,1979] 
C. fragile Gastric [Jirku, et al., 2008] 
C. galli Proventriculus  [Ryan, U.M. et al.,2003] 
C. hominis* Small intestine  [Morgan-Ryan, U.M. et al.,2002] 
C. 
macropodum 
Unknown [Power and Ryan, 2008] 
C. 
meleagridis* 
Intestine  [Slavin, D.,1955] 
C. molnari Stomach  [Alvarez-Pellitero, P. and Sitja-
Bobadilla, A.,2002] 
C. muris* Stomach  [Tyzzer, E.E.,1907] 
C. parvum Small intestine  [Tyzzer, E.E.,1912] 
C. ryanae Unknown [Fayer, R., et al., 2008] 
C. 
saurophilum 
Intestinal and cloacal mucosa  [Koudela, B. and Modry, D.,1998] 
C. serpentis Stomach  [Levine, N.D.,1980] 
C. suis Small intestine  [Ryan, U.M. et al.,2004] 
C. varanii Gastric [Pavlásek, et al., 1995] 
C. wrairi Small intestine  [Vetterling, J.M. et al.,1971] 
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sporozoites.  Micronemes are rod-like in appearance and excrete several proteins that 
function in gliding motility and attachment. These include thrombospondin related 
adhesive protein (TRAP-C1), as well as a number of glycoproteins (Langer and Riggs, 1999, 
Riggs, et al., 1999, Barnes, et al., 199, Ward and Cevallos, 1998).  C. parvum possesses a 
single rhoptry, which is membrane-bound and plays a role in transforming the attachment 
site into the parasitophorous vacuole (Chen, Et al., 2004, Smith, 2005, Boulter-Bitzer, Et 
al., 2007).  Dense granules remain distributed throughout the organism, and their 
function has not been fully elucidated.  It has been proposed that they enable exchange 
between the Cryptosporidium parasite and the host cell and modify the host cell 
(Blackman and Bannister, 2001).  In other apicomplexans, the function of dense granules 
is at least partially related to protein transport and formation of the parasitophorous 
vacuole (Cesbron-Delauw, 1994, Carruthers, Sibley, 1997).   
 
Figure 3.  
Cryptosporidium 
sporozoites excysting from 
an oocyst.  The oocyst opens 
along a suture line (Su) 
releasing sporozoites (Sp) that 
may infect nearby epithelial 
cells (Smith, et al., 2005). 
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Host cell invasion 
  Upon attachment to the host cell, the host cell membrane envelops the sporozoite 
into an intracellular, but extracytoplasmic, parasitophorous vacuole (Figure 4).  The 
signals that trigger the formation of this vacuole are not known, although it appears that 
contact with the extruded rhoptry triggers morphologic changes in the host cell membrane 
character, causing the microvilli to become less apparent and the surface of the cell to 
smooth out and begin to extend around the attached zoite (Valigurová, A., et al., 2008).  
The parasite apparently causes sphingolipic-enriched membrane microdomains (SEM) in 
the host cell membrane to congregate.  It activates enzymes involved in creating 
aggregation of these SEMs and this is tied to the remodeling of the host cell membrane.  
Actin remodeling within the host cell necessary for formation of the parasitophorous 
vacuole also seems to be tied to this activity (Nelson, et al., 2006).  Another host cell 
function that is hijacked by Cryptosporidium is the control of water influx at the site of 
infection.  The parasite triggers the host cell to increase the amount of water within the 
membrane, and this facilitates the protrusion of the host cell membrane around the 
parasite (Chen, et al., 2005).This is unusual among coccidians, as most form their own 
parasitophorous vacuoles without engaging host resources (Sibley, 2004).  The 
micronemes become more organized longitudinally in the organism, and appear to form 
the pellicle for attachment.  The position of the Cryptosporidium parasite is termed 
“epicellular” as it never comes into direct contact with the cytoplasm, remaining outside of 
the host cell membrane (Valigurová, A., et al., 2008).  A feeder organelle, ostensibly a 
nutrient transport conduit from the host cell, has been observed (Figure 1). 
Asexual reproduction: Type I merogony 
 When the parasitophorous vacuole is fully developed with the parasite within, it is 
referred to as a meront.  The parasite within the meront, now referred to as a trophozoite, 
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undergoes asexual division, resulting in the development meront.  Merozoites are 
structurally similar to sporozoites (Fayer, et al., 2008).  Type I of 4-8 merozoites within 
the meronts are the first type formed and contain 6-8 merozoites.  When the merozoites 
have matured, the host cell membrane ruptures and they escape the meront and infect 
more host cells, continuing the infection.   
Asexual reproduction: Type II merogony  
Following a number of cycles of merogony, a different type of meront, a Type II 
meront, is formed.  The merozoites from Type II meronts are believed to develop into 
either microgamete (male), or macrogametes, (female). The trigger for development of 
Type II meronts is not known for Cryptosporidium.  Morphological differentiation 
between types I and II meronts is based on the number of merozoites within each.  
Although researchers have not yet found differentiating markers for Type I and II meronts, 




Figure 4.  Attachment of sporozoites and formation of tropozoites.  A.  An 
electron micrograph shows a sporozoite being enveloped by host cell membrane 
(arrowhead).  The host membrane can been seen advancing along the sporozoite, 
tightly enveloping it.  The microvilli (mv) of host epithelial cells are visible near 
parasites.  B.  Developmental stages of Cryptosporidium.  Trophozoites  mature into 
merozoites within parasitophorous vacuole.  A ruptured merozoite (arrow) reveals 






may provide the ability to positively identify the two different types of meront (Rider and 
Zhu, 2008).   
Sexual reproduction: Gametogony 
Sexual reproduction, or gametogony, is initiated when host cells are infected with 
merozoites that develop into microgamonts and macrogamonts, rather than meronts 
(Current and Reese, 1986).   
Microgamonts are multinucleate and develop up to sixteen microgametes while 
macrogamonts contain only one nucleus.  Microgametes, which are released and attach to 
the host cells containing macrogamonts, penetrate and fertilize the macrogamonts 
(Current and Reese, 1986).  Upon fertilization, a zygote is formed.  This develops into a 
sporulated oocyst containing four sporozoites (Fayer, et al., 2008, Thompson, et al., 
2005).  Both thin-walled and thick-walled oocysts are produced and are released from the 
host cell membrane. Thin-walled oocysts reinfect the current host, and thick-walled 
oocysts are the form observed in the environment. They are shed in the feces and may 
continue the infectious cycle in another host. 
Advantageous characteristics 
Cryptosporidium species have unique characteristics that allow their persistence in 
a wide variety of environments.  A robust environmental life stage, low infectious dose, 
and a complex life cycle that can be carried out in a single host synergize with the 
intracellular, extracytoplasmic position within the infected host cell to provide advantages 
to the persistence and propagation of the Cryptosporidium parasite.  
The infectious dose (ID50) of C. parvum has been experimentally determined to be 
as low as 132 oocysts in healthy human subjects (DuPont, et al., 2005).  In C. hominis 
infections, the ID50 may be as low as 10 oocysts (Chappell, et al., 2006).  This low 
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infectious dose can explain why contamination of recreational water supplies can cause 
outbreaks.  A single swimmer shedding oocysts is able to shed enough oocysts to infect 
numerous people.  The low ID50 also means that a large volume of water is not needed to 
infect someone; a swallowed mouthful of water could contain enough oocysts to cause an 
infection.   
Cryptosporidium is monoxenous, which is advantageous in that the complete life 
cycle can be carried out once an infection is established, rather than needing transfer from 
one host to another.  This is more typical of the Gregarines than the Coccidians, as most 
coccidians carry out their life cycle in multiple hosts, rather than monoxenously (Kopecná, 
et al., 2006).   
Cryptosporidium exploits a distinctive mechanism of parasitism within the host 
cell that is not shared by any other known parasite.  It exists in an epicellular location 
outside of the host cytoplasm in a parasitophorous vacuole within the host cell membrane.  
As the parasite is covered by the host’s membrane, it escapes direct detection by antibodies 
or immune cells, as an extracellular parasite would be.  Secondly, by avoiding contact with 
the cytoplasm, Cryptosporidium avoids detection via presentation through the MCH Class 
I pathway as an intracellular parasite would be. In addition to its placement in an 
immunologically protected niche, this mechanism may allow Cryptosporidium parasites to 
share the host pool with other parasites without direct competition.   
Oocyst structure 
The structure of the oocyst wall has at least three distinct layers.  The outer layer is 
made up of glycoproteins (Reduker, et al., 1985a; Harris and Petry, 1999).  The rigid 





organism.  And the thick inner layer is made up of filamentous glycoprotein lipid (Bonnin, 
et al., 1991) .  Recently, a more detailed organizational structure has been proposed (Fig. 5, 
Jenkins, et al., 2010).  This model shows four layers; the glycocalyx, a lipid layer, a high-
protein layer, and an inner polysaccharide layer.  
Due to the complex life cycle of the organism the formation of an oocyst has not 
been directly observed, but a number of the molecules that make up the oocyst have been 
identified.  The Cryptosporidium oocyst wall protein (COWP) family of 8 proteins is 
unique to the Cryptosporidium species, but homologs have been detected in Toxoplasma 
species, suggesting that the COWP proteins play a structural role in environmental 
survival of cysts  (Templeton, et al., 2004).  Using monoclonal antibodies (Ab), COWP1 
and COWP8 have been localized to the inner layer of the oocyst wall.  These proteins are 
useful for identification of the oocyst stage and may provide drug targets for treatment.  
Unique glycoproteins that are thought to tether sporozoites to the oocyst wall in C. 
parvum (Chatterjee, et al., 2010) may also provide potential targets for identification. 
Thin-walled oocysts contain four sporozoites, just as the thick-walled oocysts do, 
but they are only covered with a membrane.  Lacking the thick, multi-layered wall of thick-
walled oocysts, they are too fragile to survive shedding and environmental stresses (Fayer, 
 
  
Figure 5.  Suggested thick-walled oocyst wall structure.  
Four distinct layers provide strength and resistance to 
environmental influences, and from chemical treatments (Jenkins, 
et al., 2010). 
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et al., 2008).  Thin-walled oocysts excyst while still within the host intestine, continuing 
the autoinfectous cycle until the host’s immune system clears the infection. 
With both sexual and asexual stages, the Cryptosporidium life cycle allows a rapid 
increase in parasite numbers within the host, reinfection of the same host, and efficient 
transport of infectious forms to new hosts.  Multiple members of the phylum Apicomplexa 
have both sexual and asexual reproductive stages, and in some species, the triggers that 
cause the switch to sexual stages have been defined.  For example, the coccidian Eimeria 
tenella is genetically preprogrammed to switch to gametogeny after two generations 
(McDougald and Jeffers, 1979).  However, it is not known what the trigger for gametogony 
is in Cryptosporidium species. 
Life cycle terminology 
 Apicomplexans, in general, replicate by both asexual and sexual processes; all are 
parasites; and all possess the characteristic apical complex in their infectious stage, which 
defines their classification.  The stages of the life cycle consist of asexual merogony, sexual 
gamogony, and sporogony in which infectious cysts are formed (Levine, 1988).  The life 
cycle of Cryptosporidium is similar to those of other members of the Apicomplexa.  
However, the vocabulary of the Apicomplexa group is complicated by similar stages and 
similar cycles that are sometimes referred to by different names.   
 In Cryptosporidium, the infecting oocyst contains four mature sporozoites, which 
escape the oocyst during excystation to invade host cells.  Once a sporozoite or merozoite 
is completely enveloped in the host membrane, it rounds up and becomes a trophozoite.  
The trophozoite is an asexually-reproducing feeding form. The trophozoite undergoes 
asexual reproduction (merogony), producing daughter merozoites.  When merozoites are 
produced, the intracellular organism is now a meront.  The mature meront bursts and the 
merozoites infect new cells, becoming trophozoites and starting the cycle anew.  
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Transmission: Route of infection  
 Cryptosporidium is transmitted by a fecal-oral route.  Human-to-human 
transmission can be through contact with an infected person’s feces or through contact 
with contaminated surfaces, drinking water, recreational water, or food sources.  Improper 
hand washing and diaper changing practices can expose people to oocysts (Fayer, et al., 
2000).  Water-borne infections and outbreaks were first noted in 1984.  Oocysts can be 
found in drinking water, due to fecal contamination of water sources and failures in water 
treatment.  Rivers and lakes can become contaminated by run-off containing the feces of 
infected animals.  Recreational water sources are now being recognized as a common 
source of oocysts and even the chlorine treatment of residential swimming pools will not 
kill the hardy thick-walled oocyst.  (Fayer, et al., 2000, Casman, 2000).    
Zoonotic transmission can occur in several ways.  C. parvum is the most common 
zoonotic species, but several other species of Cryptosporidium have been detected in 
human outbreaks (see Table 3).  Fecal contamination of water sources by infected cattle or 
other domesticated animals can affect bodies of water used by humans who may drink or 
swallow the contaminated water and become ill.  People working around infected farm 
animals can also contract cryptosporidiosis by coming into direct contact with the animal 
feces (Fayer, et al., 2000, Xiao, et al., 2004).  Although Cryptosporidium has been 
detected on fresh produce, most likely due to rinsing with contaminated water, it is 
unknown how many people have actually contracted cryptosporidiosis in this way (Yoder, 
et al., 2010).  A 2012 outbreak in England and Scotland that sickened 300 people was 
linked to pre-washed salad mix (Health Protection Agency, 2013). 
Cryptosporidiosis 
Human cryptosporidiosis is characterized by severe, watery diarrhea, often with 
stomach cramps and low-grade fever.  Patients may also suffer from a loss of appetite, 
18 
nausea, and vomiting (Yoder, et al., 2010).  Cryptosporidiosis is self-limiting in 
immunocompetent individuals.  However, when immunocompromised individuals are 
infected, chronic diarrhea can result in life-threatening dehydration.  Until the AIDS 
epidemic introduced cryptosporidiosis as a potentially life-threatening condition, 
definitive diagnoses were not routinely made.  AIDS patients, immunosuppressed patients, 
very young or very old patients, as well as those suffering from poor nutrition are at 
increased risk of severe disease or death from cryptosporidiosis (Hunter and Nichols, 
2002).   
Course of disease in the immunocompetent host 
Acute human cryptosporidiosis is characterized by severe, watery diarrhea and 
stomach cramps. Contributing symptoms may include low-grade fever, nausea, anorexia, 
and vomiting (Yoder, et al., 2010).  There is some evidence that symptoms are dependent 
upon the infecting species.  C. homins infections are more frequently associated with 
severe symptoms (Cama, et al., 2008, Gatei, et al., 2006).  After oocysts are ingested, there 
is an incubation period of 2 - 7 days before symptoms appear (Ramierez, et al., 2004, 
Jokipii and Jokipii, 1986).  Acute clinical symptoms can last as few as 2 days or as many as 
120 days.  The average duration of symptoms is one to three weeks (Jokipii and Jokipii, 
1986, MacKenzie et al., 1995, Robertson, et al., 2002).  Oocyst shedding typically is 
detected a couple days following the onset of symptoms (Chappell, et al., 2006).  Although 
shedding (patent period) typically lasts only a week or two, cases of healthy patients 
shedding oocysts for up to several months after their symptoms have stopped have been 
documented (Yoder, et al., 2010, Fayer, 2004). 
Sporadic recurrence of cryptosporidiosis within individuals is documented in many 
cases.  Some research groups have estimated 30-40% of infected patients have recurrent 
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infections.  When species identification has been carried out, C. hominis is the most 
frequently detected in recurrent cases (MacKenzie, et al., 1995, Hunter, et al., 2004b). 
Course of disease in the immunocompromised host 
Immunocompromised patients, whether suffering from HIV/AIDS, undergoing 
chemotherapy, or impacted by other forms of decreased immune function, are not able to 
clear a Cryptosporidium infection. The chronic diarrhea can quickly lead to dehydration 
and, in severe cases, death (Hunter and Nichols, 2002).  In addition, HIV/AIDS patients 
are more likely to become chronically infected with Cryptosporidium and to experience 
extra-intestinal atypical infections.  Cryptosporidium infections have been observed 
throughout the gastrointestinal tract, in the gall bladder, pancreatic duct, the respiratory 
system, and the biliary tree of HIV/AIDS patients (Chen, et al., 2002, Baishanbo et al., 
2006).  The severity of cryptosporidiosis in the context of severe immunodeficiency seems 
to be directly related to the CD4+ T-cell count.  Patients with CD4+ T-cell counts 
>200/mm3 have no more severe symptoms than immunocompetent patients, while AIDS 
patients with CD4+ T-cell counts <50/mm3 tend to have chronic, severe symptoms with 
high mortality rates (Hunter and Nichols, 2002).   
 Hunter and Nichols also reported on cryptosporidiosis in immunocompromised 
individuals who did not have HIV/AIDS.  The disease is not nearly as prevalent in this 
population as with HIV/AIDS.  Although often contradictory, general findings show that 
only immunodeficiencies causing T-cell deficiencies are likely to cause more severe 
symptoms if the patient contracts cryptosporidiosis (Hunter and Nichols, 2002). 
Pathology of cryptosporidiosis 
 The pathology of cryptosporidiosis on the human intestine involves physical 
changes to the intestinal lumen, increased porosity and secretory action of the intestines, 
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damage to host cells, and loss of fluids (Chen and LaRusso, 1999).  In immunocompetent 
individuals, epithelial changes are observable by endoscopy and biopsy.  These include a 
loss of the microvillous nature of the intestinal epithelial cells and a blunting of the villi.  
In addition to blunting, other changes to the villi that have been observed include atrophy 
and hyperplasia of crypt cells.  Furthermore, the lamina propria shows evidence of an 
influx of immune cells (Meisel, et al., 1976; Farthing, 2000).   
 Changes in intestinal electrolyte concentrations may be responsible for the influx of 
fluids, which cause the watery stools associated with cryptosporidiosis.  A combination of 
decreased sodium absorption and increased chloride secretion due to changes in epithelial 
cells creates a hypertonic environment, which causes a net flow of fluids into the intestines 
(Argenzio et al., 1990).  In addition to increased fluids, the disruption of epithelial integrity 
reduces absorption of fluids, increasing the effect (Adams et al., 1994; Griffiths et al., 
1994).  Colonoscopy or biopsies from HIV/AIDS patients show intestinal epithelial tissue 
damage that is evident at a much larger degree than in that of immunocompetent patients.  
It is believed that the lack of intraepithelial lymphocytes enables the parasite to damage 
the tissue without challenge (Hunter and Nichols, 2002). 
 Cryptosporidium has also been shown to exhibit some control over host cell 
apoptotic pathways.  Early in the infection, apoptosis is inhibited.  The mechanism is not 
understood, but host pro-apoptosis genes are down regulated during initial stages of 
infection.  Later, when meronts are mature and merozoites need to escape the host cell, 
pro-apoptotic genes are up regulated, killing the cell and freeing the parasites from the 
host cell (Liu, et al., 2008, Liu, et al., 2009, Platner and Soldati-Favre, 2008). 
Host immune response 
Although the precise mechanism by which the immune response eliminates the 
infection is not well understood, the host does eventually clear the Cryptosporidium 
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parasite.  Adult murine models have shown that early in the infection interferon gamma 
(IFN-) production by intraepithelial CD8+ cells in the host intestine increases (Barakat, 
2009, Leav, 2005).  This cytokine is believed to be important in a protective host response 
since a C. parvum infection may be established in IFN- knockout mice while those with 
normal or exogenously supplemented IFN- quickly clear the parasite (Leav, 2005).   
In humans, T cell-mediated immunity appears to play an important role in 
eliminating Cryptosporidium and protecting intestinal epithelial cells from damage (Leav, 
2005).  In personnias with HIV/AIDS, disease severity and chronicity varies inversely with 
the number of CD4+ lymphocytes in the patient’s blood.  This is not clearly understood, 
but it would seem that CD4+ cells play an important role in triggering release of IFN-γ 
(Hunter and Nichols, 2002).   
 Recovery from cryptosporidiosis is believed to confer at least a low level of 
immunity to the infecting species.  The fact that young children are far more likely to 
develop clinical disease suggests that exposure earlier in life provides some resistance to 
infection later (Chalmers and Davies, 2010).   
Current treatment and chemotherapy options 
 Finding an effective treatment for the prevention or cure of cryptosporidiosis has 
proven elusive.  Cryptosporidium species have not responded to drugs that are effective 
against other coccidian parasites (Thompson, et al., 2005).  Various antibacterial drugs 
have been tested against Cryptosporidium in vitro, and a there have been a few clinical 
trials in humans, but only two drugs have been tested in-depth as anti-Cryptosporidial 
treatments (Rossignol, 2010).  Paromomycin, an aminoglycoside that targets ribosomes, 
showed initial promise in reducing the number of episodes of diarrhea and the number of 
oocysts shed in AIDS patients.  Subsequent testing showed mixed results, and 
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Paromomycin is not regularly used to treat cryptosporidiosis (Rossignol, 2010, Hewitt, et 
al., 2000, Theodos, et al., 1998, Fichtenbaum, et al., 1993). 
 Nitazoxanide is currently the only drug routinely used to treat cryptosporidiosis. 
Since several aromatic dicationic molecules have shown anti-parasitic potential, a study 
was done testing them for efficacy against Cryptosporidium parvum in particular.  Of the 
compounds tested, nitazosanide and paromomycin showed promise for reducing the 
number of parasites in the infected mice (Blagburn, et al., 1998).  Full-scale clinical trials 
were carried out, and although it did not improve the outcome for HIV/AIDS patients, 
nitazoxanide was approved for use in non-immunosuppressed children and adults 
(Rossignol, 2010).  The mechanism of action appears to be interference with the 
pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, 
which is necessary for Cryptosporidium metabolism (Amadi, et al., 2002, Giles and 
Hoffam, 2002).  As stated earlier, it appears that the most effective treatment for 
cryptosporidiosis in immunocompromised patients is treatments to partially restore 
immune function, such as HAART (Amadi, et al., 2002, Gomez-Morales, 2004).   
Potential treatments for cryptosporidiosis  
A recent study tested 39 derivatives of nitazoxanide against nitazoxanide for 
effectiveness.  Substitutions were made for the nitro group on the thiazole ring and/or for 
one or more of the R groups on the benzene ring.  Some of the new compounds show 
higher levels of action against Cryptosporidium than nitazoxanide, particularly those with 
halogens substituted for the nitro group (Gargala, et al., 2010).  While promising, these 
drugs are in the early phases of testing, so it will be years before they would be feasible 
clinical treatments. 
Recently, a research group investigating drugs that target an apicomplexan 
topoisomerase similar to bacterial topoisomerases has found that antibiotics will target 
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Apicomplexans in addition to bacterial species.  However, Cryptosporidium is not affected 
by this mechanism of antibiotic action as it lacks an apicoplast organelle (García-Estrada, 
et al., 2010). This demonstrates once again the difficulty of finding suitable drug targets 
for Cryptosporidium.  
Vaccination has not yet been effective for cryptosporidiosis prevention, although 
recent work in an animal model using a DNA vaccine encoding for C. parvum surface 
proteins Cp12 and Cp21 has showed excellent results in early testing.  These antigens are 
the dominant immunogens in the immune response to C. parvum.  In the study, 
vaccinated mice produced anti-C. parvum Ab and also resisted infection when challenged 
with C. parvum (Yu, et al., 2010).  It will remain to be seen if this protective effect will be 
reproducible in humans or if the vaccine is cross-protective for other Cryptosporidium 
species. In addition, another surface protein, Cp15, which is immunodominant has shown 
some promise as a vaccinogen.  A successful vaccination program would be significant, 
especially in developing countries with poor health care and limited access to treatment 
(Manque, et al., 2011).  Barriers to an effective vaccination program, if such a vaccine is 
developed, would include the high cost of vaccination programs and vaccination would not 
eliminate malnourishment, which can also reduce immunocompetency. 
Epidemiology: Surveillance and outbreaks 
Since cryptosporidiosis was first classified as a reportable condition in 1995, the 
number of U.S. cases has increased from a low of 2,426 in 1996 to a high of 11,657 cases in 
2007 (Montelbano, et al., 1997, Yoder, et al., 2010).  This is likely an underestimation, as 
testing isn’t common unless there is a concern that the patient’s immune system is 
compromised.  The CDC has recently reviewed the criteria for reporting cryptosporidiosis.  
This will probably decrease the number of cases reported, as a case must now exhibit both 
the defined symptoms of the disease and be identified as Cryptosporidium by positive 
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laboratory testing to be reported.  Previously, positive lab identification, even in 
asymptomatic individuals was reportable (Yoder, et al., 2010).   
Outbreaks of cryptosporidiosis are more frequent in summer months, due to 
increased participation in water recreation activities at municipal pools, water parks, and 
swimming areas.  Oocysts entering the water from a single infected person may infect 
many others.   Since many of the mechanisms that control pathogens are not effective in 
eliminating the robust, chlorine-tolerant oocyst, municipal water systems are at risk for 
Cryptosporidium contamination and have the potential to infect large numbers of citizens.    
Cryptosporidiosis has the potential to have economic and social impact, in addition to 
health concerns, even among immunocompetent people.  When recreational water sources 
can become contaminated, and many people are affected at one time, there is going to be 
impact on multiple levels.  There are a number of outbreaks already documented. 
Milwaukee outbreak 
In the spring of 1993, over the course of two months, an epidemic of watery 
diarrhea plagued Milwaukee, Wisconsin.  Laboratory tests confirmed many cases of 
cryptosporidiosis.  Using statistical methods and telephone polling, the number of 
Cryptosporidium cases was estimated to be as high as 403,000 (MacKenzie, et al., 1995).  
Estimates range from 50-100 fatalities related to this outbreak (Hoxie, et al., 1997).  
Although the cause of the outbreak was not identified, increased turbidity in one of the 
city’s water plants was noted in the weeks preceding the outbreak and some of the water 
plant’s filters had been incorrectly installed.  It was assumed that oocysts had passed 
through the water treatment plants and to many of the residents of that city, resulting in 
the largest cryptosporidiosis outbreak ever recorded.  This outbreak illustrated deficiencies 
in current policies and spurred changes in treatment and monitoring of water treatment 
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(Zhou, et al., 2003).  Since 1993, water purification and treatment plans have been revised 
to improve removal of oocysts and increase monitoring for the parasite. 
England outbreak:  Rabbit genotype 
An outbreak in England in 2008 was traced to infection of the municipal water 
supply in Northamptonshire, England when a rabbit infected with Cryptosporidium sp. 
rabbit genotype died in a remote ancillary water tank in the reservoir that supplied 
250,000 residents ("Sickness bug found," 2008).  Thirty-four laboratory-identified cases 
of cryptosporidiosis were checked for genetic homology to the parasite isolated from the 
dead rabbit. Of these, a majority (23) matched the newly identified rabbit genotype 
(Chalmers, et al., 2009).  The other samples were either not able to be typed or were 
genotypes other than rabbit. This was unusual because the rabbit genotype is not typically 
considered pathogenic to humans.  Despite a notice for citizens to boil their water, more 
than two dozen cases of cryptosporidiosis were reported (“Sickness bug found, 2008).     
Outbreak among firefighters in Indiana and Michigan 
 An unusual outbreak occurred in June of 2011 when 20 firefighters reported 
cryptosporidiosis following a response to a barn fire.  The barn housed 240 week-old 
calves, many of which were infected with C. parvum.  In addition, a swimming pond 
nearby that was used as a water source to extinguish the fire was also contaminated with C. 
parvum. Disease surveillance revealed that fire fighters who had direct contact with calves 
(carrying or leading them from the barn), who washed themselves in water from the 
swimming pond, or who drank water from a cooler of with an unidentified source were 
more likely to have gastrointestinal disease (Wilczynski, et al., 2012). 
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Water treatments to remove Cryptosporidium oocysts 
In addition to surviving environmental stresses, the oocysts are also highly 
resistant to chemical treatment.  The current chlorine treatment commonly used to kill 
bacteria and viruses in municipal water systems does not kill the Cryptosporidium oocysts 
(Fayer, et al., 2000, Casman, 2000).  Municipal water treatment plants must remove 
particulate material from source water to prevent the Cryptosporidium oocysts from 
contaminating drinking water.  Typical water treatment removes Cryptosporidium during 
two stages.  First, source water is allowed to stand in reservoirs for several weeks allowing 
much of the particulate matter, including oocysts, to settle to the bottom, which will die 
after several weeks (MacKenzie, et al., 1994).  Coagulation using agents that encourage 
particles to clump together, followed by flocculation, which stirs water, increasing 
coagulation, also removes Cryptosporidium oocysts.  Filtration further removes any 
remaining oocysts.  Other mechanisms to eliminate oocysts are being trialed, such as UV 
light treatment, and are showing some promise for eliminating Cryptosporidium sp. from 
water supplies (Betancourt and Rose, 2004). 
Research challenges 
Research on Cryptosporidium began in earnest when it became recognized as a 
pathogen of economic concern for cattle ranchers, as it can dramatically affect calf weight, 
and that it could cause severe disease in immunocompromised humans (Thompson, 
2008).  Research includes a focus on many aspects of cryptosporidiosis, including 
epidemiology, pathology, immunology, and chemotherapy, as well as understanding the 
life cycle, species identification, and host-specificity of Cryptosporidium sp. 
Laboratory studies of Cryptosporidium are challenging due to the complex life 
cycle of the organism.  C. parvum, the zoonotic species that infects humans, does not 
infect small laboratory model animals such as rats or mice unless they are 
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immunocompromised.  An infection with C. parvum can be initiated in neonatal mice less 
than three weeks of age, but these infections produce few oocysts. After about three weeks, 
the murine immune system matures and is resistant to infection by C. parvum.  
Additionally, neonatal mice are difficult to work with due to their small size.  C. parvum 
does infect cattle, and this host is used to propagate oocysts.  However, the cost, 
maintenance, and size of these animals limit their use in many experimental situations.  
Available Cryptosporidium isolates  
 Isolates of Cryptosporidium species are available from a limited number of 
sources.  Oocysts can be obtained from laboratories that either amplify the parasite in 
calves or in immunocompromised mice.  Due to these limited options for in vivo 
propagation, maintaining a large number of different Cryptosporidium species for 
research is not practical.   The American Type Culture Collection (ATCC) currently has 
seven strains of Cryptosporidium available for use.  These are listed in table 4 along with 
the depositors of each strain. 
Culturing techniques and limitations 
Cell culture techniques have been employed for growing and studying 
Cryptosporidium in vitro.  Three of the most often used cell lines include human colonic 
adenocarcinoma (Caco-2), human colonic tumor (HCT-8), and Madin Darby canine 
kidney (MDCK).  These cell lines will support a Cryptosporidium infection through oocyst 
production (Arrowood, 2002).   
 A standard method for growing C. parvum in vitro is to infect a nearly-confluent 
monolayer of mammalian cells with oocysts and then incubate this cell culture in medium 
containing up to 10% serum at 37ºC under 5% CO2.  An infection may progress for up to 
several days.  In vitro infections allow both sexual and asexual stages to be observed.  All 
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life stages of C. parvum can be observed using cell culture techniques; however, culture 
conditions limit the duration of the active infection.  Maintaining the infection is possible 
only as long as the host cell monolayer is viable.  Host cell death in the monolayer and a 
lack of access to new host cells for infection contribute to the difficulty in successfully 
maintaining a long-term in vitro infection (Arrowood, 2002).  Multiple techniques have 
been used to attempt to slow host cell growth, and hence, overcrowding of the monolayer 
and cell death.  These include lightly irradiating the host cells prior to infection and 
limiting the amount of serum available in the culture medium.  This has extended the 
length of infections up to two weeks (Hijjawi, 2010). 
A method utilizing a micro-gravity environment and a rotating cell-culture system 
has been developed to study Cryptosporidium infections.  Using observations of three-
dimensional cell culture growth on the Space Shuttle, cell culture using an apparatus to 
create a situation that will keep cells in suspension results in development of what has 
been coined “organoid” growth (Hammond, et al., 2000).  Cells begin to differentiate and 
more closely resemble an intestine than a monolayer of cells.  Pseudo-villi develop with 
fringed border cells.  This provides a more realistic model of Cryptosporidium pathology 






87664 Cryptosporidium serpentis KSU-2 SJ Upton, 
 NV Khramtsov 
87666 Cryptosporidium muris 108735 SJ Upton,  
NV Khramtsov 
87668 Cryptosporidium parvum IowaI SJ Upton,  
NV Khramtsov 
 
87712 Cryptosporidium parvum UCP SJ Upton,  
NV Khramtsov 
87715 Cryptosporidium sp. VS1742 Idaho-1 SJ Upton, 
 NV Khramtsov 
87763 Cryptosporidium parvum Galicia NV Khramtsov,  
SJ Upton 
87765 Cryptosporidium parvum Columbia NV Khramtsov,  
SJ Upton 
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than traditional cell culture (Warren, et al., 2008).  This could be significant for 
Cryptosporidium research as it much more closely replicates the normal environment for 
Cryptosporidium infections, and could provide a better look at the effect on host cells and 
the behavior of the parasite.  
Understanding and identifying life stages 
Microscopic examination of stained Cryptosporidium infections can be used to 
determine the life stage the parasite.  Staining and identification of structural differences 
using differential interference contrast (DIC) microscopy can aid in identifying various life 
stages.  Type I meronts contain 6-8 merozoites while Type II meronts contain only four.  
Figure 6 illustrates that differentiation of these stages can be accomplished with 
fluorescence (A) or DIC microscopy (B).    
 
 
Commercial rapid stain kits are available to aid in identification.  Sporo-Glo ™ 
from Waterborne, Inc. uses polyclonal, fluorescein-labeled rat anti- Cryptosporidium 
 
Figure 6.  Type I and Type II meronts.     
 (A) A photomicrograph of a Type 1 meront bearing six 
fluorescently stained merozoites (yellow).   
(B) A photomicroph of a Type II meronts utilizing 
Differential Interference Contrast microscopy to 




parvum antibodies to label intracellular stages.  Sporozoites and merozoites can be labeled 
to fluoresce green under fluorescent microscopy.  Waterborne’s Crypt-a-Glo™ uses mouse 
anti-oocyst monoclonal antibodies labeled with fluorescein to label Cryptosporidium 
oocysts  
Immunohistochemical staining of Cryptosporidium is also used for microscopic 
study.  A variety of monoclonal and polyclonal antibodies are available.   
Currently, there are no staining methods that can differentiate between Type I and 
Type II meronts.  Antibodies are able to detect either intracellular stages, or oocyst 
structure, but differentiating between Type I and Type II meronts remains subjective.  
Some lectins have been shown to bind to certain glycoproteins on Cryptosporidium cells 
and oocysts.  Using labeled lectins to stain infected monolayers of host cells can allow the 
Cryptosporidium cells to be visualized either with fluorescent or chromogenic stains. 
Genetic analysis 
PCR analysis can be used to determine genetic expression at various stages of an 
infection.  Actively growing and dividing cells express 18S rRNA, which has been used as 
a baseline RNA level to monitor the development of the infection using real-time PCR.  
Traditionally, a declining level of 18S has been used as a marker of a failed or 
nonproductive infection.  Some of the genes that have been used for study include COWP1 
- 9, TRAP, and HSP70. (Templeton and Kaslow, 1997; Robson et al., 1998; Spano, et al., 
1997). 
Objectives of the project 
The long-term objective of this research project is to understand the role of host-
pathogen adaptations in health and disease. A critical aspect of this research is the 
development of standardized laboratory techniques that can be used to examine changes 
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in Cryptosporidium infection.  This research project represents a first step in determining 
the critical aspects of Cryptosporidium infection that signal the vitally important switch 
from asexual to sexual life cycle stages that indicate the production of infectious 
organisms.  The central hypothesis of this work is that the switch from an asexual to a 
sexual stage is a function of the availability of host cells to infect rather than a time-
dependent switch.  
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CHAPTER 1:  UTILIZATION OF A FETAL MOUSE MODEL OF 
CRYPTOSPORIDIOSIS FOR IMMUNE STUDIES 
Introduction 
 Cryptosporidium parvum is a zoonotic species that primarily infects humans and 
young calves of domestic cows, causing the diarrheal disease cryptosporidiosis 
(O’Donoghue, 1995, Thompson et al., 2005).  This organism is difficult to study in the 
laboratory setting due in large part to the lack of productive infection models with which 
the life cycles of the human pathogen can be studied under experimental conditions.  
Laboratory rodents older than 3 weeks do not develop C. parvum infections and do not 
shed oocysts (Ernest, 1986).   Larger animals, such as rabbits, canines, or non-human 
primates, do not produce an active infection when exposed to C. parvum.  While they are 
used to propagate infectious oocysts for commercial research purposes, calves are not cost-
effective research laboratory subjects due to the size of the animals and the high price of 
housing and upkeep. Further, the large volume of diarrhea produced in an active infection, 
high concentration of oocysts in the calves’ feces, and contamination of the animals’ hides 
with infectious organisms presents a particular safety concern for transmission to animal 
care workers.   
Laboratory mouse models of C. parvum infection require either the use of neonates 
less than 3 weeks old or knockout mice with compromised immunity (Ungar, 1990).  
Knockout mice are not an ideal choice, due to the fact that the immune response is 
impacted by the lack of important components, thus presenting a skewed view of the 
disease process within a host.  A neonatal mouse model can be a useful tool for observing 
pathological changes within the intestine and other immune responses.  However, these 
animals are difficult to work with due to their small size and the delicacy required handling 
them without harming them.   
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 To evaluate a murine laboratory model for future work elucidating the 
immunological reaction of the host to the parasite, we initiated a short-term neonatal 
mouse model using 21-day-old BALB/c mice.  Two days after inoculation with C. parvum 
oocysts, the mice were euthanized.  The distal ileum of each animal was cut into 0.5-cm 
segments, mounted in paraffin, and cut into 5-µm sections.  Changes in the infected mouse 
intestine were then observed by light microscopy using various staining techniques.    
Materials and methods 
Animals and institutional use compliance 
 BALB/c mice were obtained from Jackson Laboratories (Bar Harbor, ME).  
Animals were housed in a specific pathogen-free facility with ad libitum access to food and 
water on a 12-h light:dark cycle. All experiments were performed in accordance with 
guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) of North 
Dakota State University.  
Infection of neonatal mice with C. parvum  
 One mouse was administered 0.2 mL sterile PBS via gastric gavage with a blunt 
18-gauge needle to serve as an uninfected control.  Each of the other two mice was 
administered 1 × 107 C. parvum oocysts in 0.2 mL sterile PBS in the same manner to 
establish experimental infection animals.   
Collection and preparation of tissue samples from neonatal mice 
At 24 h post-infection, all three mice were euthanized and the small intestine was 
dissected from each mouse.  The terminal 60% of the ileum was flushed with sterile PBS, 
using a sterile syringe and blunted needle.  This was followed by a 10% formalin flush.  The 
intestine sections were fixed in 10% formalin solution for approximately 5 h.  Specimens 
54 
were cut into 0.5-cm sections, and several sections were embedded on end in a single 
paraffin block, which was then cut into cross-sectional 5-m slices and mounted on glass 
microscope slides for evaluation.  Paraffin embedding and sample preparation was done 
by the NDSU VDL histology lab.  Deparaffinized and dehydrated tissue slides were 
obtained for tissues from each mouse.  Representative sections from each mouse were 
stained with hematoxylin and eosin (H&E).  Slides were stored at 4C until they were 
viewed under transmitted light microscopy for evidence of infection.   
Lectin-VVL staining of tissue sections  
  In the initial staining procedures, a Lectin VVL-biotin (Vector Laboratories, 
Burlingame, CA) kit that was successfully used to stain Cryptosporidium intracellular 
stages in cell-culture monolayers was used to stain the murine intestine sections.  
However, the non-specific staining of mouse epithelial tissues resulted in an unacceptable 
level of background staining.  The procedure was modified to include avidin/biotin-
blocking steps, using reagents provided in the AEC-HRP Cell and Tissue Staining kit (R&D 
Systems, Minneapolis, MN) in an attempt to reduce background. While gains were made 
in reducing background staining, a protocol for staining the tissue sections with lectin for 
C. parvum without significant background staining was not perfected, and further 
optimization would be necessary to use this in tissue samples. The results are included to 
show the attempted optimization of the staining protocols. 
 Tissue sections affixed to glass slides were circled with a hydrophobic PAP pen 
(Abcam, Cambridge, MA) to provide a barrier for reagents.  Several drops of 1% Triton X-
100® (Union Carbide, Greensburg, LA) in PBS were added to cover the tissue sections.  
Slides were incubated at room temperature for 10 min.  The Triton X-100® solution was 
removed before blocking.   
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  Tissues were blocked with a bovine serum albumin (BSA) solution to prevent non-
specific binding.  Several drops of 0.5% BSA in PBS were added to cover each section, and 
the slides were incubated for 10 min at room temperature.  The blocker was removed and 
four rinses of 3-4 drops of PBS was added to each section then removed by vacuum pipet. 
 Non-specific binding of lectin was blocked using the avidin-blocking reagent from 
the Cell and Tissue Staining kit (R&D Systems).  This step was used to bind any 
endogenous avidin-binding sites in the tissue.  Three to four drops of avidin blocking 
reagent were added to each section and incubated for 15 min at room temperature.  This 
was followed with three rinses with the buffer supplied in the Cell and Tissue Staining kit 
(R&D Systems). 
 Following avidin blocking, the tissues were incubated with biotin to saturate any 
free biotin-binding sites on the avidin.  Three to four drops of biotin blocking reagent were 
added to each tissue section and incubated at room temperature for 15 min.  The blocking 
reagent was removed, and tissues were rinsed three times with rinse buffer. 
 Lectin-VVL, isolated from Vicia villosa (hairy vetch) seeds binds to certain surface 
glycoproteins on Cryptosporidium parvum.  Using biotinylated lectin-VVL (R&D 
Systems), it is possible to stain cell cultures to observe infected cells and Cryptosporidium 
morphology.  Lectin-VVL-biotin was added to each tissue section and incubated at room 
temperature for 30 min.  The solution was removed and the slides were rinsed three times 
with PBS.   
 To avoid quenching the fluorescent label, the overhead lights were turned off in the 
lab for the following step, and the procedure was carried out in the ambient light from a 
window in the lab.  Streptavidin-CY3 reagent (R&D Systems) was added to the tissue 
sections and incubated in the dark at room temperature, for 30 min.  The reagent was 
removed and slides were rinsed once with PBS.  Slides were protected from light and 
stored at 4C when not being viewed. 
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Immunohistochemical staining of tissue sections 
 Immunohistochemical staining was carried out using a mouse anti-C. parvum Ab 
received from A. Sheoran, Tufts University in North Grafton, Massachusetts.  Slides were 
placed in slide holders and loaded into a microwave pressure cooker. The pressure cooker 
was filled with 1.5 L 10-mM citric acid and locked.  The pressure cooker was microwaved 
until one minute after the pressure indicator stem popped.  The pressure cooker was 
removed from the microwave and allowed to sit for 10 min.  The top was then removed, 
and the pressure cooker was allowed to cool for another 20 min.    
 After cooling, the slides were removed, and the samples were covered with 100 L 
peroxidase blocker (R&D Systems) for 30 min at room temperature, after which slides 
were rinsed for 5 min in rinse buffer (PBS + 0.05% Tween20, VWR, Aurora, CO) on a 
rocker for agitation.  The slides were then incubated with a serum-blocking reagent (R&D 
Systems).  Reagent was removed, and the sample was quickly washed in rinse buffer.  
Avidin blocking reagent (R&D Systems) was added, and the samples were incubated at 
room temperature for 15 min, and then rinsed in PBS.  The final blocking reagent, biotin-
blocking reagent (R&D Systems) was added to the sample for 15 min at room temperature.  
This was rinsed off and excess buffer was blotted.  
 The samples were covered with mouse anti-C. parvum polyclonal Abs which had 
been diluted 1:5 in Ab diluent (Appendix) then incubated overnight at room temperature.  
Three 15-min washes in rinse buffer were used to remove excess primary Ab.  The 
secondary Ab was biotinylated goat anti-mouse IgG diluted 1:200 in Ab diluent (R&D 
Systems). The slides were incubated at room temperature for 30 min and then washed 3 
times for 15 min each in rinse buffer.   
 High sensitivity streptavidin (HSS) conjugated to horseradish peroxidase (HRP, 
R&D Systems) was added to the tissue sections and allowed to incubate at room 
temperature for 30 min. This was followed by three, 2-min washes in rinse buffer.  HSS 
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has high affinity and specificity for the biotinylated secondary Ab, while the HRP causes an 
enzymatic reaction with the chromogen, allowing visualization of the labeled cells.  The 3-
amino,9-ethyl-carbazole (AEC) chromogen was mixed with the chromogen buffer (R&D 
systems) immediately before use.  Several drops of the chromogen solution were added to 
cover the tissue specimens.  The HRP-catalyzed reaction of AEC produced a dark pink 
pigment.  Development was monitored under a microscope until the pigment was dark 
enough to be easily observed. The slides were rinsed in distilled water, followed by a 5-min 
distilled water wash.  A 10-sec dip in Gill’s hematoxylin III (Surgipath, Richmond, VA) was 
used to counterstain the sections.  This was followed with two, 2.5-min washes in water.  
Cover slips were mounted with Aqueous Mounting Medium (Vector Labs) and dried 




Figure 7.  H&E-stained distal ilium from 
naïve neonatal or C. parvum-infected 
BALB/c mouse. The normal villi are regularly 
formed and narrow (A), while villi from mice 
inoculated with 1 × 107 C. parvum oocysts, 24 h 
post-infection are shorter with blunted ends. (B) 
Magnification 200X.   
 
 
Figure 8.  H&E-stained distal ilium 
from neonatal BALB/c mouse 24 h 
after being inoculated with 1 × 
107 C. parvum oocysts. The yellow arrows 
indicate C. parvum oocysts in the intestinal 




H&E staining  
 Cryptosporidium infection may cause intestinal villi blunting in infected mice 
(Garza, et al 2008).  H&E-stained sections were evaluated for physical changes, and the 
gross anatomy of naïve and infected intestines were compared.  Intestines from naïve mice 
showed long, narrow villi with sharp distal points (Fig 7A), while the villi from the infected 
mice appeared shorter and blunter (Fig 7B), even in sections where no Cryptosporidium 
cells were observed.  The intestines from the infected mice also had irregular margins that 
were distorted, compared to the naïve mouse (Fig 7).  Figure 8 shows C. parvum oocysts 
visible in intestinal crypts on the H&E-stained sections of intestine from the infected 






 When stained using Lectin-VVL, the tissue sections showed unacceptable levels of 
non-specific staining (Fig 9A).  Mouse tissue was labeled in many places, making 
identification of C. parvum difficult or impossible, due to the inability to differentiate 
between mouse tissues and C. parvum.  Adding additional blocking steps did not result in 




Figure 9.  Lectin-VVL stain and modified Lectin-VVL stain of 
C. parvum-infected mouse intestines.  The Lectin-VVL bound to 
the parasite and also to glycoproteins on the intestinal cells, causing 
background staining (A).  Additional blocking did not decrease the 
background staining (B).  Magnification 60X 
 
 
Figure 10.  IHC-stained tissue from C. 
parvum-infected BALB/c mouse ilium.  C. 
parvum was clearly visualized (pink, center of 




 The use of anti-C. parvum Ab in the IHC protocol yielded clear labeling of 
C. parvum within the tissue sections without background staining (Fig 10).  This staining 
confirmed that the infected mouse intestines retained C. parvum two days following 
inoculation.   
Discussion 
Infection of neonatal mice and staining of tissues 
 In this study, we tested a neonatal model in anticipation of future studies that may 
be planned to characterize the host immune response to C. parvum infection.  Oocyst 
shedding usually doesn’t begin until at least the third day after infection; so the collection 
of fecal samples was not appropriate for this study (Petry, et al., 1995). However, we were 
able to document signs of infection in our mice at 24 h post-infection.  We interpret the 
villi blunting (Fig 7) to suggest that this model would likely have become an active 
infection in the neonatal mouse.  
The various staining methods tested on the tissue samples demonstrated the 
complexity of finding a marker that can identify C. parvum with minimal background 
binding to host cells.  The first method used a lectin stain to bind glycoproteins.  The basis 
of the lectin-VVL labeling for this stain is the presence of terminal N-acetyl-D-
galactosamine residues (GalNAc).  Unfortunately, GalNAc is also a component of intestinal 
goblet cells (Roth, 1984) and the lectin-VVL stain, which is effective in cell culture 
samples, had unacceptably high levels of non-specific binding. For the purpose of staining 
intestinal tissue sections after infection with C. parvum for immunological analysis or 
other studies, lectin-VVL staining is not a viable option. 
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Anti-Cryptosporidium IHC staining may be a more appropriate means for specific 
labeling of slide-mounted tissues.  The Abs specific for C. parvum antigens used, with the 
staining parameters used did not demonstrate non-specific binding to host cells.  We 
anticipate that as monoclonal Abs are developed for the various life stages of C. parvum, it 
will be possible to stain multiple life stages on the same sample, allowing researchers to 
more closely track the stages of infection.   
With the advent of microdissection tools, such as Laser Capture Microdissection 
(LCM), identifying specific life stages will be necessary to ensure homogenous samples for 
analysis.  As LCM techniques are perfected for dissecting single cells of interest, stage-
specific genetic characterization may be possible.  Methods for amplification of nucleic 
acids from single cells are currently being developed (Kurimoto, et al., 2006).  This opens 
the door for future research exploring the molecular and cellular interaction between the 
parasite and its host.  Identifying genetic markers for various stages of infection could lead 
to new directions in treatment of cryptosporidiosis. 
Future directions 
 This model may be applicable for short-term immunological study.  The infection 
method, although delicate, seems to be effective.  There is the potential to develop an 
alternate method of infection, using a non-invasive protocol with droppers or nipples to 
allow the neonatal mice to ingest the oocysts.  Infections allowed to progress for several 
days, up to several weeks, can allow the study of the changes in the intestines of the mice.  
Depending on the length of infection and development of the mouse, the immune system 
may be able to clear the infection itself.  In that case, there would be opportunity to 
observe the immune response as it develops.  Serological testing could include testing for 
regulation of various immune molecules.   
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 Testing on tissue sections could be expanded to include IHC staining for specific 
inflammatory cells that may be migrating to the area, such as T cells. Testing for the 
presence of increased IgA on the mucosa could also indicate immune response in the host, 
although in situ testing for specificity may be a challenge. Cryptosporidium specific IgA, 
IgG and and IgM have been observed in experimental and naturally occurring infecitons of 
calves (Kassa, et al., 1991), so serum samples from the infected mice could be evaluated for 
immune response, as well. 
 Microdissection techniques can be employed to assess responses to C. parvum in 
infected cells, while using neighboring cells as controls.  The regulation of host-cell 
apoptosis and other cell functions by C. parvum can also be monitored based on life stage 
differentiation and dissection of specific cells, either infected or non-infected.  By being 
able to select cells that share a common infection status, gene regulation can be compared 
for cells within the same host.  Using adjacent, uninfected cells in the same tissue sample 
as controls would be a marked advantage over using an uninfected host control.   
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CHAPTER 2:  DEVELOPMENT OF A CELL-CULTURE METHOD ON 
FRAMESLIDES® FOR THE USE OF LASER MICRODISSECTION IN THE 
STUDY OF CRYPTOSPORIDIUM LIFE STAGES 
Introduction 
 Cryptosporidium parvum is a zoonotic parasite that causes cryptosporidiosis.  The 
hallmark of this disease is stomach discomfort and severe diarrhea lasting up to two 
weeks.  The disease became prominent in the medical community when the increasing 
numbers of immunosuppressed persons, especially HIV/AIDS patients, began to develop 
chronic infections, sometimes causing death (Casemore, 1985, Guerrant, 1997).  
Laboratory study has proven difficult due to the lack of a satisfactory animal model of the 
disease.   
 Infection of cell cultures has allowed scientists to study the parasite’s life stages, 
but with significant limitations.  Some scientists have reported successful cultivation of 
Cryptosporidium in host cell-free culture, but this technique has not been replicated in 
other labs (Zhang, et al., 2009).  The complex life cycle of C. parvum does not progress 
indefinitely in cell culture, and although all of the life stages of C. parvum have been 
observed in cell culture, serial passage has not been demonstrated.   
Developing a method for positive identification of life cycles of Cryptosporidium 
will allow closer study of individual stages and ultimately can provide insight into the 
trigger for switching from asexual to sexual reproduction.  This is an important trigger to 
understand, as it marks the point where the parasite begins to be shed in the feces of the 
host and potentially to be spread to secondary hosts.  As such, the trigger for the switch to 
sexual reproduction may offer a target for chemotherapeutic agents against 
cryptosporidiosis.  While cell culture does produce the various life stages of the parasite, 
including production of oocysts, there is no current method to accurately identify various 
66 
intracellular stages.  Microscopic identification of Type I and Type II meronts is a 
subjective and time-consuming process.  However, the potential for developing 
monoclonal antibodies for specific life-stages does exist if Type I and Type II meronts 
could be isolated and unique markers were found and exploited.  
There are several cell lines that have been used to study C. parvum.  Human 
ileocecal adenocarcinoma (HCT-8), stomach adenocarcinoma (AGS), and colorectal 
adenocarcinoma (Caco-2) are three lines of human cells that support growth of various 
Cryptosporidium species.  The Madin-Darby canine kidney (MDCK) cell line is also 
commonly used for cell culture of Cryptosporidium (Yu, et al., 2000, Arrowood, 2002).  
MDCK cells are fast-growing, are not as fastidious as other cell lines, and provide a level 
cell monolayer in which to observe the C. parvum life cycle in a relatively constant focal 
plane, making them well-suited for this experiment.  The NDSU DNA Forensic Laboratory 
provided use of the laser microdissection microscope for these experiments. As they were 
in the process of being accredited as a crime lab, an additional factor in choosing the non-
human MDCK cells was that they would be an unlikely source of contamination for human 
forensics. 
The guiding principles for this work were that cell culture in Chamber slides™ 
(Thomas Scientific, Swedesboro, NJ) would allow the side-by-side comparison of multiple 
variations of different factors, such as host cell density, infectious dose, and growth 
medium components.  Following incubation, staining or immunohistochemistry (IHC) 
could be carried out on the chamber slides to allow observation and analysis.  Host cells 
and Cryptosporidium cells could then be collected from individual chambers for analysis 
of gene expression under different conditions.  However, one limitation of using a whole 
chamber for analysis is that it does not allow sorting of oocysts, meronts, merozoites, and 
host cells so it is not always certain which life stage is expressing the genes detected.  For 
example, the control of host cell apoptosis is a function that is of particular interest to 
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researchers that is not well understood at present.  It is known that Cryptosporidium can 
regulate host cell apoptosis, and targeted genetic analysis would provide insight into the 
genes that control this function (Liu, et al., 2008, Liu, et al., 2009, Plattner and Soldati-
Favre, 2008). 
Laser Capture Microdissection® (LCM) is a technology that can be used to 
discriminate between closely associated cells—for example, parasite-infected cells and 
their normal near neighbors or between different stages of parasite development in situ. 
Importantly, the ability to select a single, infected cell with LCM would enable genetic 
analysis of both host cells and Cryptosporidium cells in specific stages of infection.  With 
LCM, individual cells may be collected based on specific parameters.  The Positioning 
Ablation Laser MicroBeam® (PALM®) Micro-Laser system (P.A.L.M. Microlaser 
Technologies AG, Bernried, Germany) can be used to mark selected areas of a slide for 
collection.  The selected cells can then be catapulted into the collection tube with focused 
laser energy.  Once a sample is collected, DNA or RNA can be extracted from the cells for 
further experimentation.  Capturing high quality nucleic acid is critically important to the 
quality of the data that can be generated from these experiments. Membrane-coated glass 
slides allow the laser to catapult cells from the slide without destroying the cell and with 
less damage to the cell’s nucleic acid.  In a similar way, FrameSlides®  (Zeiss, Germany) 
have a membrane mounted on an open metal frame which allows the laser to cut around 
the selected cells and then to catapult them into the collection tube without damaging the 
cell or the genetic material within.   
In order to use LCM with cell culture, cells must first be grown on the slides.  Since 
flat microscope slides don’t lend themselves to cell culture, a new method was needed.  
FrameSlides® are a unique construction in which a metal platform supports a membrane, 
forming a large shallow well.  We exploited this design to repurpose the FlameSlide® for 
use in cell culture and subsequent infection with Cryptosporidium.   
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MDCK cells were cultured in both NUNC Lab-Tek I Chamber slides (Thomas 
Scientific, Swedesboro, NJ) and FrameSlides® (Zeiss, Germany) and infected with 
C. parvum oocysts.  Lectin-VVL staining and immunohistochemical staining were 
performed on each type of slide.  Microscopy was carried out on both an Olympus BX61 
with a 12 mexapixel camera for capturing images and the Zeiss PALM system, which was 
equipped for fluorescent microscopy and image capture.  Microscopic visualization of the 
fluorophor was successful only when used with cover slips and SlowFade® mounting 
medium (Molecular Probes, Eugene, OR).  To allow laser microdissection, the SlowFade® 
and coverslip had to be left off and the fluorescent signal was quickly quenched when 
exposed on the PALM microscope without use of these protecting barriers.  IHC-stained 
cells were easily observed under both microscopes and life stages were observed and 
recognized.  Chamber slides were also stained with Sporo-Glo® (Waterborne Inc., New 
Orleans, LA) for observation under fluorescent microscopy. 
Cryptosporidium life stages were photographed on Chamber Slides® using a 12 
mega-pixel camera-equipped Olympus BX61 and oocysts were collected using LCM®.  
Samples containing up to 100 C. parvum-infected cells were collected with the PALM® 
system and RNA was extracted.   
Materials and methods 
In vitro cultivation of Madin-Darby canine kidney cells on Chamber Slides® 
 Cells used for this experiment were obtained from ATCC and maintained in Dr. 
McEvoy’s lab.  All pertinent NDSU IBC protocols are followed in the use of these cell lines. 
A monolayer of MDCK cells (ATCC CCL-34) was grown to confluence at 37ºC and 
5% CO2 and was used for subculture.  Growth medium was removed and cells were rinsed 
with serum-free Minimal Essential Medium (MEM, Appendix).  Six milliliters of 0.25% 
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trypsin (Gibco, Grand Island, NY) was added to the monolayer and incubated at room 
temperature for 15 min to detach cells from the flask.  Once the monolayer was detached 
from the surface of the flask, the flask was knocked firmly on one side to dislodge the cells.  
Six milliliters of MEM with 10% FBS was added to the culture flask to suspend the cells 
and to inactivate the trypsin.  A 100-µL aliquot of the cell suspension was added to 100 µL 
of trypan blue working solution (Appendix), and cells were counted using a 
hemacytometer.  The cells were pelleted by centrifugation and resuspended at a 
concentration of 1.7  105 cells/mL in MEM plus 10% FBS. 
NUNC Lab-Tek I Chamber slides (Thomas Scientific, Swedesboro, NJ) were seeded 
with 1 mL of the cell suspension and incubated for 24-48 h at 37°C and 5% CO2 in a 
hydrated chamber.  Cells were observed periodically using an inverted microscope to 
determine confluency.  When an estimated 70%-80% of the chamber slide surface area 
was covered with MDCK cells, the cells were infected with oocysts. 
Infection of MDCK cells in Chamber Slides® with C. parvum 
 C. parvum (Iowa isolate) oocysts were obtained from Waterbourne, Inc. (New 
Orleans, LA).  The oocyst concentration was 6.25  105/mL in PBS with 1 mM Sigma 
A5955 antibiotic/antimycotic.  For each sample, 8.0 L of the oocyst suspension was 
added to a 1.5-mL centrifuge tube (5  104 oocysts/tube).   The tubes were centrifuged at 
20,000 g for 3 min.  The oocysts were then suspended in 200 µL of 10% (vol:vol) bleach 
solution and incubated for 10 min at 4°C.  Following this incubation, cells were centrifuged 
at 20,000 g for 3 min, and the supernatant was removed.  Oocysts were washed in sterile 
PBS three times to remove the bleach. Following the third wash, oocysts were resuspended 
in 500 µL of infection medium (Appendix).  
Chamber slides with monolayers of 70-80% confluent MDCK (ATCC CCL-34) cells 
were removed from the incubator and medium was removed.  The infection medium 
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containing the oocysts was added to each well.  A negative control well containing only 
infection medium and MDCK cells was included.  Chamber slides were returned to the CO2 
incubator for 3 h to allow excystation and for the released sporozoites to infect the MDCK 
cells.  Infection medium was removed and 1 mL MEM with 10% FBS was added to each 
well for incubation.    
Cells were incubated for 24-48 h, the growth medium was removed, and cells were 
rinsed twice with 1 mL PBS.  Cells were fixed for staining by incubating in 1 mL of 4% 
formaldehyde for 30 min at room temperature.  This solution was removed and cells were 
washed twice in PBS.  
Infection of MDCK cells with C. parvum with bile-salt excystation  
An alternate excystation/infection protocol, based on current published literature 
showing an improved efficiency of excystation and infection by saving one step of 
handling, was trialed for this study.  Briefly, the oocysts were incubated for 30 min at 37ºC 
resuspended in a 0.8% solution of the bile salt sodium taurocholate (NaTC) following the 
bleach treatment and rinses.  Following this incubation, cells were centrifuged at 20,000 
g for 3 min, and the supernatant was removed.  Oocysts were washed in sterile PBS three 
times. Following the third wash, oocysts were resuspended in 500 µL of infection medium.  
Oocysts were resuspended in 1 mL of infection medium and the incubation was allowed to 
proceed uninterrupted.  Subsequent steps of the protocol remained the same as the bleach 
treatment protocol.  There was no observable difference in the results obtained from the 
two different infection protocols. 
In vitro cultivation of MDCK cells on FrameSlides®  
 FrameSlides® (Zeiss, Germany) were used to enable the collection of C. parvum 
cells with the PALM® laser microdissection pressure catapulting microscope (Zeiss).   
Prior to cell culture, the FrameSlides were placed in a slide-holder and sterilized by 
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gamma irradiation in a 137CsCl irradiator (dose 8600 Gy).  The sterile FrameSlide was 
removed from the container with sterile forceps and placed in a sterile Petri dish until use.  
A suspension of 1.7  105 MDCK cells/mL was prepared in MEM with 10% FBS.  The 
FrameSlide® was carefully loaded with 1.4 mL of the cell suspension, allowing the growth 
medium to completely cover the membrane and well up above the side of the frame.  The 
Petri dish containing the FrameSlide® was carefully placed in the 37°C incubator with 5% 
CO2 and incubated overnight.  The culture was observed periodically until the cells were 
80% confluent on the membrane, and the FrameSlide® was prepped for infection as 
previously described for chamber slides. Extra care was needed when handling the slide to 
avoid spilling the medium.  A PAP pen (Abcam, Cambridge, MA) was used to create a 
hydrophobic barrier around the edge of the FrameSlide® and minimize the spilling of 
culture medium.  The PAP pen line was drawn slightly back from the edge of the 
membrane, to avoid possible chemical interaction with the membrane. 
Infection of MDCK Cells on FrameSlides® with C. parvum 
Oocysts were prepared using the bleach-only excystation technique above, and a 
1.0 mL suspension of infection medium containing 1  106 oocysts was made.  The growth 
medium was removed from the membrane slide and the oocyst suspension was added to 
the membrane.  The culture was incubated at 37°C with 5% CO2 for 48 h.  It was necessary 
to change the infection medium after 24 h due to change in pH of the small volume of 
medium.  When it started to turn orange/yellow, it was removed and replaced with MEM 
plus 10% FBS.  At 48 h, the FrameSlides® were removed from the incubator, and the 
growth medium was removed.  The cells were fixed with HistoChoice® (AMRESCO, Solon, 
OH) fixative for 30 min at room temperature, and the samples were stored at 4°C until use. 
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Lectin-VVL staining of infected MDCK cells 
 Monolayers on the FrameSlides® were permeabilized with 1 mL 1% TritonX-100® 
(Union Carbide, Greensburg, LA) in PBS for 10 min at room temperature.  One milliliter of 
the TritonX-100® solution was added to each well and incubated at room temperature for 
10 min.  After permeabilization, the TritonX-100® solution was removed and the MDCK 
cells were blocked with a solution of 0.5% bovine serum albumin (BSA) in PBS for 10 min 
at room temperature to prevent non-specific binding. 
 Lectin VVL-biotin (Vector Laboratories) was diluted to a 1% w/v solution in PBS 
containing 0.5% BSA and stored at -20°C until use.  The working solution was thawed 
before use, and 1 mL was added to each FrameSlide®and incubated for 30 min at room 
temperature.  After incubation, the lectin solution was removed and the FrameSlides® 
were rinsed 3 times with 1 mL PBS. 
Biotin-conjugated Lectin-VVL was labeled with conjugated Strepavidin-CY3 
fluorophore, diluted to 1 µg/mL in PBS, by incubating at room temperature for 30 min 
under low light to preserve this light-sensitive reagent.  After incubation, cells were 
washed twice with 1 mL PBS per chamber.   
The chamber walls were removed from the slide, using the tool provided by the 
supplier.  To mount the cover slip, 8 µL Slow Fade mounting medium was added to each 
chamber.  The slides were stored at 4°C until used for microscopic analysis.   
Sporo-Glo® staining of infected MDCK cells 
 Chamber slides were used to culture MDCK cells according to previous methods, 
which were then infected with oocysts.  Following removal of growth medium and rinsing 
in PBS, slides were stained with Spro-Glo® (Waterborne, Inc., New Orleans, LA) 
according to manufacturer’s instructions.  To mount the cover slip following staining, 8 µL 
SlowFade® mounting medium was added to each chamber.  Slides were stored at 4°C 
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until they were analyzed using fluorescence microscopy.  The FITC filter was used to 
observe the cells. 
Immunohistochemical staining of C. parvum-infected MDCK cells on chamber slides 
 MDCK monolayers growing on chamber slides were infected as described 
previously.  Following incubation, growth medium was removed and cells were rinsed with 
MEM.  Monolayers were fixed with HistoChoice® (Amresco, Solon, OH) for 30 min at 
room temperature.  HistoChoice® was removed, and the plastic chambers were removed 
from the slides with the tool provided by the manufacturer. 
The slides were incubated with a serum blocking reagent (R&D Systems).  This 
reagent was removed, and the sample was quickly washed in rinse buffer.  Avidin blocking 
reagent (R&D Systems) was added, and the samples were incubated at room temperature 
for 15 min, then rinsed in PBS.  Biotin blocking reagent (R&D Systems) was added to the 
sample for 15 min at room temperature. The sample was rinsed, and excess buffer was 
removed by blotting.  
The samples were incubated with mouse anti-C. parvum polyclonal Abs diluted 1:5 
in Ab diluent (Appendix) overnight at room temperature.  Three, 15-min washes in rinse 
buffer were used to remove excess primary Ab.  The secondary Ab was biotinylated goat 
anti-mouse IgG diluted 1:200 in Ab diluents (R&D Systems). The slides were incubated at 
room temperature for 30 min and then washed 3 times for 15 min each in rinse buffer.   
High sensitivity streptavidin (HSS), conjugated to horseradish peroxidase (HRP, 
R&D Systems) was added to the tissue sections and allowed to incubate at room 
temperature for 30 min. This was followed by three, 2-min washes in rinse buffer.   
HSS has high affinity and specificity for the biotinylated secondary Ab, while the 
HRP causes an enzymatic reaction with the chromogen, allowing visualization of the 
labeled cells.  The 3-amino,9-ethyl-carbazole (AEC) chromogen was mixed with the 
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chromogen buffer (R&D systems) immediately before use.  Several drops of the 
chromogen solution were added to the tissue specimens.  The HRP-catalyzed reaction of 
AEC produced a dark pink pigment.  Development was monitored using bright field 
microscopy until the desired color intensity was achieved. The slides were rinsed in 
distilled water, followed by a 5-min distilled water wash.  A 10-sec dip in Gill III 
hematoxylin (Surgipath, Richmond, VA) was used to counterstain the sections.  This was 
followed with two, 2.5-min washes in water.  Slides were cover-slipped using Aqueous 
Mounting Medium (Vector Labs) and dried vertically on a paper towel. 
Staining C. parvum-infected MDCK cells on FrameSlides®  
 The lectin-VVL protocol that was used to stain chamber slide specimens was also 
used to stain fixed monolayers of MDCK cells.  The only modifications to the protocol were 
that the volumes of the various liquid reagents were increased to 1.4 mL from 1.0 mL to 
account for the larger surface area and, following the final rinse, the FrameSlide® samples 
were not coverslipped, but were taken immediately to the LCM facility for laser dissection. 
 Immunohistochemical staining was also used on FrameSlide samples. Again, 
reagent volumes were increased to account for increased sample surface area.  Aliquots of 
240 L of each reagent were used to cover the monolayer on the membrane.  Following the 
chromogen step and rinses, FrameSlides were taken immediately to the LCM facility. 
Collection of cells using laser microdissection 
 The system used for laser microdissection was the Positioning Ablation Laser 
MicroBeam® (PALM®) Micro-Laser system (P.A.L.M. Microlaser Technologies AG, 
Bernried, Germany).  Prior to using the laser, a safety check was done to ensure that the 
iris diaphragm was open in the epifluorescence beam path, no filters were in the laser 
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path, the filter block on the unit was set to the “laser” position, and that the FL shutter in 
the microscope was open according to the operation manual.   
 Slides were mounted in the PALM® Robostage holding frame.  The PALM® 
CapMover was loaded with three 50-µL LPC-Microfugetubes (P.A.L.M. Microlaser 
Technologies AG, Bernried, Germany) each with 20 µL of RNAlater® (Applied 
Biosystems/Ambion, Austin, TX) added to the inside of the cap.   The RoboMover® 
software was used to indicate into which cap the specimen would be collected, and the 
sample was observed under light microscopy using the Zeiss Axiovert 200M (Zeiss, 
Germany) microscope attached to the PALM® system.   
 Using a non-essential area on the slide, laser focus and energy was optimized.  To 
determine the laser settings, a zig-zag line was drawn on the screen using the freehand 
tool.  The nitrogen (337 nm) laser was fired, and as it moved along, the focus was adjusted 
up and down in the plane of the specimen to focus the beam (narrowest cut path).  Once 
focus was determined, energy was reduced and the process was repeated.  The ideal energy 
yields a very narrow, neat line which stops working as soon as the focus is adjusted up or 
down at all.  Ideal laser focus and energy for cutting and catapulting were determined with 
glass slides and FrameSlides® with MDCK monolayers.  Table 5 lists the settings used for 
these experiments.  
 The lectin-VVL-prepared slides were observed using a fluorescein isothiocyanate 
(FITC) filter.  Labeled C. parvum cells were marked using the system software and cells 
were removed by laser dissection and catapulted into the microfuge tube cap.  Both the 
rectangle tool and the autocircle tool in the PALM® software were used to mark the areas 
of interest and catapult the samples into the collection tube. 
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Table 5.  Laser settings on PALM® system for MDCK monolayer slides 
Slide Material / Objective Cut  LPC® 
 Energy Focus Energy Focus 
Glass slide, 40X 45 16 53 8 
Glass slide, 63X 46 25 55 10 
FrameSlide®, 20x 43 57 70 60 
FrameSlide®, 40X 44 50 65 51 
FrameSlide®, 63X 51 36 73 52 
 
 The FrameSlides® were labeled using IHC and were observed under light 
microscopy to label C. parvum cells.  Rectangular sections were cut and catapulted in sizes 
ranging from 10 x 10 µm to 86 x 86 µm.  Rectangles were marked in areas that had 4-8 C. 
parvum cells each.  The autocircle function was used to cut and catapult individual C. 
parvum cells.  Separate tubes were collected containing approximately 50, 100 and 300 C. 
parvum cells.  These cells were pelleted by microcentrifugation, and RNA was extracted 
using and RNeasy™ kit (QIAGEN) according to manufacturer’s instructions. All required 
filters and buffer solutions were provided in the kit.  Concentration of RNA for each 
sample was measured using an ND-1000 spectrophotometer (Nanodrop®, Wilmington, 




Fluorescent staining of in vitro infections of MDCK cells by C. parvum  
Fluorescent microscopy, utilizing a FITC filter, and differential interference 
contrast (DIC) microscopy were used to observe the Lectin-VVL-stained C. parvum on 
chamber slides.  Oocysts, Type I meronts, Type II meronts, and merozoites were observed. 
Intracellular meronts were identified, and individual merozoites were visible within the 
meront.  Type I meronts were readily identified, as 6-8 merozoites could be visualized 
(Figure 11, left panel).  The same meront observed under fluorescent microscopy was also 
observed with DIC microscopy surface morphology was observed  (Figure 11, right panel). 
 Type II meronts were difficult to identify, since the differences in the visual plane made 
counting the four merizoites very challenging.  Figure 12 shows a DIC image of a Type II 
meront.   
  
Figure 11.  C. parvum Type I meront (arrow) 
in MDCK cell culture, 24 h post-infection with 
C. parvum oocysts.  At least 5-6 individual 
merozoites are clearly visible in lectin-VVL-stained 
specimens visualized with fluorescent microscopy 
using a FITC filter (left panel) or differential 
interference contrast (DIC, right panel).  TM: 1000X 
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 Merozoites that had only partially erupted from the parasitophorous vacuole were 
observed.  By using a combination of DIC and fluorescence, an image showing the glowing 
merozoites along with surface structure and detail was captured (Figure 13). 
 Fluorescence staining on FrameSlides® required leaving out the steps using Slow 
Fade, due to the interference it would cause with the laser microdissection.  Initially, the 
Cryptosporidium cells were visible under fluorescence microscopy, but quickly faded 






Figure 12.  Type II meront in 
MDCK cells culture, 24 h post-
infection with C. parvum.  
Differential interference contrast (DIC) 
microscopy shows four individual 




Figure 13.  MDCK cell with 
erupting merozoites. A combination 
of fluorescence and DIC microscopy 
show morphology of a MDCK cell (A) 




Immunohistochemical staining with anti-C. parvum Ab. 
 The Ab showed clearly against the background of MDCK cells.  These were 
counterstained with a 1-s dip in hematoxylin (Figure 14).  Very little non-specific staining 
was observed.  IHC staining on FrameSlides® was effective for use with the PALM system, 
as the stain was easily visible onscreen and didn’t fade with light.  
 
 
Capture of C. parvum cells via laser microdissection 
 RNA was extracted from the batches of cells captured via LCM™.  Tubes containing 
50, 100, and 300 C. parvum meronts yielded 11.0 ng/L, 10.4 ng/L, and 8.5 ng/L of 
RNA in 10 L of RNA solution, respectively.  Unfortunately, this did not equate to 
quantities that were large enough to successfully identify C. parvum by PCR.   
Discussion 
 LCM™ provides enormous opportunities for cellular and genetic research in many 
fields.  Combined with monoclonal antibody labeling techniques, a number of specific cells 
 
Figure 14.  C. parvum meront, shown 
on infected MDCK cells.  C. parvum was 
stained using anti-C. parvum Ab and HSS-
HRP as a chromogen.   
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or structures can be differentially labeled and separated for analysis.  Breakthroughs in 
criminal investigation lend some insight into the possibilities open to a multitude of 
research fields.  Currently, forensic analysts can use Y chromosome-specific markers from 
a small sample, allowing them to find and capture sperm cells from a swabbed slide (Elliot, 
et al., 2003).  Applying the same type of selective labeling, researchers can isolate specific 
populations of cells or substances and use genetic analysis on close-to-pure samples of 
DNA or RNA. 
 Cryptosporidium research has many facets that remain largely unexplored; due to 
the relatively short time it has been of clinical interest.  One aspect that is particularly 
interesting is understanding the trigger that causes the parasite to switch from asexual 
reproduction for replication within a host to sexual reproduction and passage of oocysts 
from the host.  Since it is thought that Type II meronts precede gametogony, the ability to 
cull only Type I or Type II meronts from an infected tissue sample or cell culture sample 
would allow comparison for differential gene expression.  Understanding the trigger for 
the switch could provide information for development of chemotherapy or vaccination to 
prevent the spreading of the parasite.   
 While all of the functions aren’t fully clear yet, it is accepted that the genes for 
Cryptosporidium Oocyst Wall Proteins (COWP1-8) play an important role in the sexual 
reproduction of Cryptosporidium.  These proteins are exclusively located in the oocyst 
walls, so being able to detect up regulation of the genes could signal the switch to sexual 
reproduction.  Using LCM™ to selectively collect Type I and Type II meronts for 
comparative analysis could lead to detection of Type-specific markers to positively identify 
meronts and the stage of the life cycle the parasite is in. 
 The development of cell culture techniques directly on FrameSlides® for infection 
studies is a big step.  New staining techniques that overcome the shortcomings of the 
current techniques are needed to assist in this endeavor.  While one-step fluorescent 
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labeling is possible, the fast fading of the fluorescence limits functionality of these for 
LCM™.  IHC techniques specifically label Cryptosporidium cells, but the process itself 
seems to be damaging to RNA, which prevents analysis of gene expression.  Development 
of a one or two-step chromogenic stain could be the solution and is one possible direction 
to follow.  Development of water-free IHC techniques could limit the reactivation of 
endogenous RNases, which is a possible cause of the RNA damage (Tangrea, et al., 2001). 
Another possibility worth exploring would be to see if Liquid Cover Glass (Zeiss, 
Germany) would be useful in fluorescent staining for LCM.  This is designed to be used in 
conjunction with the P.A.L.M.™ system, so LCM™ is possible with the product on 
samples.  Whether the fluorescent signals would persist long enough for location and 
collection of cells would need to be determined. 
The problem of low yield of RNA could also be addressed with improved RNA 
amplification.  It is possible to amplify the RNA from a single cell, using of commercial kits 
(Lang, et al., 2009).  However, the kits are quite expensive and would not address the issue 
of RNA damage caused by IHC.  Utilization of some form of RNA amplification would be 
likely to improve LCM™ results. 
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CHAPTER 3:  TIME SERIES INFECTION IN MDCK CELLS TO STUDY SHIFT 
FROM ASEXUAL TO SEXUAL REPRODUCTION 
Introduction 
 Cryptosporidiosis is a parasitic, diarrheal disease caused by the apicomplexan 
Cryptosporidium.  The disease is of clinical concern as immunocompromised patients may 
develop chronic diarrhea that may have fatal consequences (Casemore, 1985, Guerrant, 
1997).  The disease is typically contracted through contaminated recreational or drinking 
water.  The infectious oocysts withstand chlorination; so can be persistent, even in treated 
water (Fayer, et al., 2000, Casman, 2000).   
Cryptosporidium parvum is one of two species that most frequently cause human 
cryptosporidiosis: the other is Cryptosporidium hominis (Ernest, et al., 1986, Zu, et al., 
1992).  C. parvum has a complicated life cycle that includes an environmental infectious 
stage consisting of infectious oocysts being shed in the feces of hosts.  Once ingested, the 
parasite typically establishes infection in the small intestine.  Within the host, there are 
two types of reproduction.  Asexual reproduction, merogony, in which repeated 
generations of Type I meronts produce merozoites that infect other cells within the host 
occurs first.  Type II meronts, which are thought to produce merozoites that develop into 
gametes and oocysts are formed.  The trigger for switching from asexual to sexual 
reproduction is not understood for Cryptospordium (Current and Reese, 1986).  For some 
of the apicomplexans, there are a certain number of generations of merogony before sexual 
reproduction begins.  In others, such as malaria, there is a coordination based on time of 
generation cycles (McDougald and Jeffers, 1979).     
Oocysts are of two forms. Thin-walled oocysts seem to function to perpetuate the 
infection in a single host through autoinfection. Thick-walled oocysts are shed in the feces, 
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are very resistant to many environmental conditions, and are infectious to new hosts 
(Current and Reese, 1986, Current and Garcia, 1991).   
Although the mechanism by which C. parvum switches its reproductive cycle has 
not been elucidated, a possible trigger may be the availability of fresh host cells to infect.  
Our hypothesis for this study was that merogony continues as long as there is an available 
source of uninfected cells for the merozoites to enter.  Once the cells in an area of the 
intestine–or experimentally, in the cell culture flask–have been saturated, sexual 
reproduction allows for migration out of the host or to a new area of host tissue for 
autoinfection.    
 In order to explore the effect of host-cell availability on the timing of the life cycle, 
a series of infections was carried out using variations in cell confluency and variations in 
inoculation size to simulate high- and low-density infections.  Then, the transcription of 
genes that produce life stage marker proteins was assessed.  The marker used for early life 
cycle was the actin gene, since actin rearrangement is a part of the initial invasion process 
(Sibley, 2004, Abrahamsen and Schroeder, 1999).  The 18S small subunit ribosomal RNA 
(SSU rRNA) was used as a housekeeping gene to track that Cryptosporidium cells were 
actively growing.  Production of oocysts signals that sexual reproduction has occurred, so, 
to test for the presence of sexual life stages, upregulation of the genes encoding 
Cryptosporidium oocyst wall proteins (COWP1 and COWP8) was measured.  qPCR 
analysis was used to determine time points at which each gene was being expressed, as 
well as a relative measure of the degree of upregulation.  
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Materials and methods 
Comparison of temporal gene expression from high- and low-density C. parvum 
infections on Chamber Slides® 
 To compare the expression of various life cycle-related genes under different 
growth conditions, an infection series was set up to have simultaneous infections with high 
and low numbers of oocysts and high and low host-cell density.  This allowed comparison 
of the impact of host cell density and oocyst infectious dose. 
 To ensure slides with the target confluency of 50% and 90% would be available, a 
range of concentrations was used to seed chamber cells.  Twenty-four chamber slides, in 
sets of six, were seeded at the following concentrations of MDCK cells (cells/mL):  1.7  
105, 1.5  105, 1.0  105, and 0.9  105 in MEM plus 10% FBS (Appendix).  These were 
incubated at 37°C with 5% CO2 in a humidified chamber for 24 h.  The slides were 
observed to determine confluency.  The chamber slides that were approximately 50% 
confluent and approximately 90% confluent were chosen for the high- and low-density 
time series.  Time points were 2 h post-infection (hpi), 6 hpi, 12 hpi, 24 hpi, 48 hpi, and 72 
hpi.  The chambers on each slide were inoculated with varying numbers of C. parvum 
oocysts:  320,000; 100,000; 10,000; and 1000 oocysts in infection medium.   
C. parvum (Iowa isolate) oocysts were obtained (Waterbourne, Inc., New Orleans, 
LA).  Oocyst concentration was 6.25  105/mL in PBS with 1 mM Sigma A5955 
antibiotic/antimycotic.  For each well, the appropriate volume of the oocyst suspension 
was added to a 1.5-mL centrifuge tube (5  104 oocysts/well).   The tubes were centrifuged 
at 20,000 g for 3 min.  The oocysts were resuspended in 200 µL of 10% bleach solution 
and incubated for 10 min at 4°C.  Following this incubation, cells were centrifuged at 
20,000 g for 3 min and the supernatant was removed.  Oocysts were washed in sterile 
PBS three times.  Washes were carried out by adding 200 µL sterile PBS, vortexing to 
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resuspend, centrifuging at 20,000 g for 3 min, and removing supernatant.  Oocysts were 
resuspended in 500 µL of 0.8% sodium taurocholate (NaTC) and incubated at 37C for 30 
min. This incubation was followed by the same rinse series as the bleach treatment.  
Oocysts were resuspended in 1 mL of infection medium. 
Chamber slides with monolayers of 70-80% confluent MDCK (ATCC CCL-34) cells 
were removed from the incubator and medium was removed.  The infection medium 
containing the oocysts was added to each well.  A negative control well containing only 
infection medium and uninfected MDCK cells was included.  Chamber slides were 
returned to the CO2 incubator for 3 h to allow excystation and for the released sporozoites 
to infect the MDCK cells.  Infection medium was removed and 1 mL MEM with 10% FBS 
was added to each well for incubation.    
Cells were incubated for 24-48 h, the growth medium was removed and cells were 
rinsed twice with 1 mL PBS.  To fix cells for staining, 1 mL of 4% formaldehyde was added 
to each well and allowed to sit for 30 min at room temperature.  This solution was 
removed and cells were washed twice in PBS by adding 1 mL to each well and removing 
with vacuum apparatus.  
These were incubated at 37°C with 5% CO2 in a humidified chamber. At each time 
point, one chamber slide from each set was removed from the CO2 chamber, and the 
infection medium was removed.  RNA was either immediately extracted or 1.0 mL 
RNAlater™ (QIAGEN, Valencia, CA) was added to the chamber to preserve RNA until 
extraction. 
RNA extraction  
Infection medium or RNAlater™ was removed from the wells and 1 mL lysis buffer 
 (Appendix) was added to each well.  Cells from each well were scraped off the slides and 
collected in separate 1.5-mL microcentrifuge tubes.  RNA was extracted from each sample 
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using an RNeasy™ kit (QIAGEN), as per manufacturer’s instructions.  All required filters 
and buffer solutions were provided in the kit.  Concentration of RNA for each sample was 
measured using an ND-1000 spectrophotometer (Nanodrop®, Wilmington, DE).  RNA was 
stored at -80ºC following extraction. 
Synthesis of cDNA 
The SMART MMLV® Reverse Transcriptase system (ClonTech, Mountain View, 
CA) was used for cDNA synthesis.  In addition to the kit components, random primers 
(Promega, Madison, WI) and 10 mM dNTP mix (Promega, Madison, WI) were used.  
Initially an 11-µL mixture with random primers and extracted RNA was made.  This 
mixture was heated at 70°C for 3 min to denature the RNA and held at 4°C to allow 
annealing of the primers to the RNA.   
The master mix contained 4 µL 5x first-strand buffer, 2 µL dNTP mix, and 2 µL 100 
mM DTT (total of 8 µL per reaction tube).  Eight microliters of master mix was added to 
each tube, and 1 µL SMART MMLV or 1 µL RNase-free water (for rt − control).  This 
mixture was incubated at 42°C for 60 min to allow synthesis of the first strand cDNA.  The 
reaction was terminated by inactivating the reverse transcriptase at 70°C for 15 min.  The 
cDNA was stored at -20°C. 
qPCR analysis of  COWP1, COWP8 and actin gene expression 
Primers and probes for COWP1 and COWP8 were available, but primers and a 
probe were needed.  Primer and probes were designed for the C. parvum actin gene using 
Primer Express 2.0 (Applied Biosystems, Carlsbad, CA).  A MGB probe with 6-FAMTM 
fluorophore and primers were obtained from Integrated DNA Technologies (Coralville, 
IA).  Sequences were verified as Cryptosporidium with BLAST; forward primer 
CATCCACCGGGTTTAGAGTTG, reverse primer GGGTTGAATGGACAATTAGGGTAT, 
probe TCTATCACTGGTCTCCCAAC. 
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Quantitative real-time PCR (qPRC) was carried out using an ABI 7500 Real-Time 
PCR machine (Applied Biosystems).  The comparative CT method, using the arithmetic 
formula 2- ΔΔCT was used to calculate the relative fold change in gene expression of COWP1, 
COWP8 and actin using C. parvum 18S as the housekeeping gene. 
Results 
Actin expression 
Actin expression levels based on fold-change data from qPCR show peak 
expression of actin genes occurring at varying time points.  Different samples had peak 
expression at 12 hpi, 24 hpi, and 48 hpi (Figure 15).  Three of the samples grown on 
confluent host cells peaked at three different times.  There is no clear relationship between  
host cell confluency or infectious dose and the expression of actin gene.  
 
  
Figure 15.  C. parvum actin gene expression over time.  Gene expression was 
measured at various infectious doses in cell cultures with either sparse (50% confluent) 
or confluent growth at the time of infection. Results are reported in terms of fold-
change as measured by qPCR, using expression of the 18S gene as a housekeeping gene. 
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COWP1 expression 
qPCR was used to measure COWP1 gene expression for samples collected over the 
time series infection.  The largest peak in expression was at 48 hpi and expression was 
downregulated at 72 hpi in all of the samples (Figure 16).  During the early part of the 
infection, up to 24 hpi, there was low-level detection of COWP1 expression in the samples 
that had been exposed to larger doses of oocysts, however this was at very low levels when 
compared to the peak expression at 48 hpi. 
Expression was upregulated and then downregulated early on in three of the 
samples grown on confluent MDCK cells.  The changes in expression are not substantial 







 COWP8 expression, based on qPCR analysis, peaked at 72 hpi in 7 of the 8 groups 
tested.  Only the sample from the confluent host cells with 320 thousand oocyst infectious 
Figure 16.  C. parvum expression over time of COWP1 gene in terms of fold-
change as measured by qPCR.  MDCK cells were grown to either 50% or total 
confluency and inoculated with varying numbers of oocysts.  Following qPCR, 
expression of COWP1 was measured against housekeeping 18S gene. 
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dose peaked earlier than that, at 48 hpi (Figure 18).  Three of the infected cultures using 
confluent host cells showed low levels of expression COWP8 at both 6 hpi and 12 hpi 
(Figure 19).  Expression dropped off completely by 24 h. With the exception of the sample 
with confluent host cells infected with 320,000 oocysts, expression sharply increased at 48 
hpi and was still prominent at 72 hpi. The samples with very high infectious doses had an 
increase in expression of the COWP8 gene at 6 hpi with downregulation at 12 hpi, with no 
expression detected at 24 hpi.  These samples had much higher expression later in the 











































Time Point (Hours Post-Infection) 
Figure 17.  Graph showing C. parvum expression over time of COWP1 
during the first 24 hpi. MDCK cells grown either to 50% confluency or 100% 
confluency were infected with varied numbers of oocysts.  The expression of the COWP1 











 In order to create conditions with varying availability of fresh host cells to be 
infected, we employed two approaches that varied in the number of targets and the 
number of infectious agents.  The number of host cells that were initially available could be 
limited by infecting cell culture flasks that had been grown to only 50-60% confluency.  
The number of oocysts in the infectious dose were also varied to give high- or low-density 
infections.  Various pilot infection series showed that using cell cultures with less than 
60% confluency did not result in productive infections (data not included).  The data for 
the series using low-confluency host cells was inconsistent and even the 18S housekeeping 
gene could not be detected in some of the samples. The experiments using confluent host 
cells for infections with varying inoculum sizes did yield measurable results, which we  
Figure 18.  C. parvum COWP8 gene expression over time (fold-change as 
measured by qPCR). MDCK cells grown to either 50% or 100% confluency were 
inoculated with a range of infectious does of oocysts and COWP8 expression was 








were able to analyze.  Our original hypothesis was disproven.  Our results indicate that 
there is not an apparent relationship between the availability of cells to infect and the 
switch to sexual reproduction.  The infections that started with very low numbers of 
oocysts switched to sexual reproduction at the same time point as the infections that were 
started with 320,000 oocysts, using the expression of COWP1 and COWP8 as a measure of 
sexual development.  Although our hypothesis was not supported, our results add to the 
body of knowledge of things that do not trigger the switch to sexual production. 
 The use of actin as an early life-stage marker does not appear to be a good choice.  
Its expression did not have consistent timing for any of the experiments.  This makes sense 
if actin remodeling is used for motility, since there are multiple rounds of merogeny, the 
actin gene would be expressed at more than one time, and not necessarily downregulated 


































Time Point (Hours Post-Infection) 
COWP8 Expression During Early Infection   
Figure 19.  Expression of C. parvum COWP8 gene (fold-change as 
measured by qPCR). MDCK cells grown to either 50% or 100% confluency were 
inoculated with a range of infectious does of oocysts and COWP8 expression was 
measured at various time points following infection using qPCR and 18S as a 
housekeeping gene.  Expression during the first 24 hpi are shown. 
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monitoring the actin gene would be to measure the length of time each cycle of merogeny 
takes, if actin is upregulated for infection and then downregulated during cell division.  
 There are still not a large number of studies looking at the expression of the various 
genes of C. parvum over time, and the existing studies leave large gaps.  Data for 6, 12, 24, 
48, and 72 hpi are readily available, but little can be found for other times.  Considering 
that our data shows peak production at 24 and 48 hpi for some of these genes, it could be 
helpful to know in more detail the times for activation.  A series of experiments using 
three- or six-hour intervals for up to 96 hours could be very useful in elucidating the 
timing of the regulation of the various COWP genes.  It may be that there is a particular 
sequence that is not being seen due to the large time gaps between sampling. 
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 Many aspects of cryptosporidiosis are still poorly understood; this is at least 
partially due to the difficulty of long-term laboratory propagation of the organism.  The 
complex life cycle of Cryptosporidium and the lack of knowledge of specific details of the 
different stages of the life cycle provide not just difficulties for research, but many 
opportunities of exploration to increase the understanding of this important zoonotic 
pathogen.  Understanding Cryptosporidium is necessary due to the implications of these 
infections in public health.  Immunocompromised patients and outbreaks caused by 
municipal and recreational water contamination provide the impetus to further study this 
organism.  
  Improving the ability to identify specific life stages, through staining techniques 
and microscopy can allow selective harvesting of cells in the same life stage, allowing 
genetic and cellular structure analysis.  These studies then can lead to creating better 
molecular markers for study of infections.  Due to the unique niche that the organism 
occupies within host cells, the mechanisms for triggering immune responses is not known.  
Specific labeling of life cycles within infected cells, coupled with surveys of the type of 
immune cells being activated could provide insight.  In addition, the development of 
receptors for specific cell structures opens the door to better chemotherapy for an infection 
that has, thus far, mostly eluded pharmaceutical intervention. 
 Use of cell culture FrameSlides™ may enable a more accurate collection of cells for 
research.  However, until immunohistochemical staining techniques that are less prone to 
activating intrinsic RNases can be developed, RNA analysis from cells collected this way 
will be limited.  The challenge is that existing commercial stains that are fluorescent need 
some sort of cover to keep the signal from being quenched, while laser microdissection 
requires that the cells be exposed for removal.  This would provide an excellent focus for a 
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project, attempting to reduce RNases during IHC to enable RNA analysis from laser 
microdissection-collected cells. 
 Laser microdissection is a tool that should prove useful in pursuing immunological 
study of Cryptosporidium infections.  Utilizing a mouse model for infection, tissue 
sections can be mounted on either FrameSlides™ or glass slides with the proper 
membranes for use with a laser for microdissection.  Cells in the area of infected cells 
could be studied, as well as the presence of various cytokines from activated immune cells.  
Being able to carefully cut away the cells adjacent to an infected cell provides the 
opportunity to study the response of host tissue to infection. 
 Although the time series study disproved our hypothesis, a much more in-depth 
time series would be invaluable to study the timing of the activation of particular genes.  
Our study was limited in order to create a high-density infection, but could be repeated 
with confluent cell cultures for a higher yield for a higher yield of Cryptosporidium.  An in-
depth time series utilizing checks every three hours, instead of six, and using multiple host 
cells lines could provide data on the activation of different genes and demonstrate if the 
life cycle is driven by the type of host cell the parasite has infected. 
 Another possible avenue that could be pursued would be that if a person is able to 
pull out cells infected with Cryptosporidium, it could be possible to try to figure out what 
antigens are being presented on the surface of the infected cells.  Knowing the structures 
that are antigenically significant could provide a direction for treatment or prevention.   
 Overall, these experiments have helped demonstrate the vast array of possibilities 






5 mL 10% Opti-MEM (Gibco BRL) 
5 mL 10% Fetal Bovine Serum 
500 L 1x antibiotic/antimycotic solution (Sigma, 100x 10,000 units 
penicillin, 10 mg streptomycin, 25 L amphotericin B/mL) 
500 L 1 mM sodium pyruvate (Sigma) 
0.4515 g 50 mM glucose 
87.5 L 35 g/mL ascorbic acid, stock solution 20mg/mL (Sigma) 
100 L 1.0 g/mL folic acid, stock solution 0.5 mg/mL (Sigma) 
100 L 4.0 g/mL 4-aminobenozoic acid, stock solution 2 mg/mL 
(Sigma) 
10 L 2.0 g/mL calcium pantothenate, stock solution 10 mg/mL 
(Sigma) 
38.702 Minimum Essential Medium Eagle with Earl’s salts, L-
Glutamine, non-essential amino acids, without NaHCO3 (Gibco) 
pH to 7.4 with 1 M NaOH or 1 M HCl 
Filter sterilize with 0.22 micron filter 
Trypan blue solution in Hank’s balanced salt solution 
0.4 g    Trypan Blue (Sigma) 
100 mL Hank’s Balanced Salt Solution, HBSS (Sigma) 
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Working Stock Solution 
0.2 mL 0.4% Trypan Blue in HBSS 
0.8 mL HBSS  
PBS buffer 
80.0 g NaCl 
11.6 g Na2HPO4 
2.0 g KH2PO4 
2.0 g KCl 
~9.8 L Deionized water (bring volume to 10.0 L) 
pH to 7.0 with 1.0 M HCl or 1.0 M NaOH 
Bleach solution 
100 mL Chlorox ® Bleach 
900 mL Deionized water 
Store at 4C 
Sodium taurocholate solution  
0.8 g Sodium taurocholate (Sigma) 
100 mL PBS buffer 
Filter sterilize with 0.22 micron filter 
1X TAE buffer solution 
50 mL 50X TAE buffer solution (Sigma) 
950 mL Deionized water 
Store at 4C 
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Trypsin solution  
2.5 g Trypsin (Gibco) 
8.0 g NaCl 
0.06g Na2HPO4 
0.2 g EDTA 
0.4 g KCl 
1.0 g Dextrose 
950 mL Deionized water 
Bring volume to 1 L with deionized water.   
Lysis buffer 
10 L Beta-mercaptoethanol (Sigma) 
1.0 L Buffer RLT plus from RNeasy ™ kit (QIAGEN) 
Mix immediately prior to RNA extraction 
 
